Cholinergic and lipid mediators crosstalk in Covid-19 and the impact of

glucocorticoid therapy

*Malena M. Pérez, Ph.D.[1]; *Vinícius E. Pimentel, B.Sc.[1,7]; *Carlos A. Fuzo, Ph.D.[1,8]

*Pedro V. da Silva-Neto, M.Sc.[1,8,9]; Diana M. Toro, M.Sc.[1,8,9]; Camila O. S. Souza,

M.Sc.[1,7]; Thais F. C. Fraga-Silva, Ph.D.[2,7]; Luiz Gustavo Gardinassi, Ph.D.[12]; Jonatan C.

S. de Carvalho[1,5]; Nicola T. Neto[1,10]; Ingryd Carmona-Garcia[1,5]; Camilla N. S. Oliveira,

B.Sc.[1,7]; Cristiane M. Milanezi, B.Sc.[2] Viviani Nardini Takahashi, Ph.D.[1]; Thais Canassa

De Leo, M.Sc.[1,8]; Lilian C. Rodrigues, Ph.D.[1]; Cassia F. S. L. Dias, B.Sc.[1,8]; Ana C.

Xavier[10]; Giovanna S. Porcel[10]; Isabelle C. Guarneri[10]; Kamila Zaparoli[11]; Caroline T.

Garbato[11]; Jamille G. M. Argolo, M. Sc[11]; Ângelo A. F. Júnior, M.Sc.[11]; Marley R.

Feitosa, M.D.[3,14]; Rogerio S. Parra, M.D.[3,14]; José J. R. da Rocha, M.D.[3]; Omar Feres,

M.D.[3,14]; Fernando C. Vilar, M.D.[4,14]; Gilberto G. Gaspar, M.D.[4]; Rafael C. da Silva,

B.Sc.[13]; Leticia F. Constant, B.M.[13]; Fátima M. Ostini, B.M.[13]; Alessandro P. de Amorim,

M.Sc.[13]; Augusto M. Degiovani, B.M.[13]; Dayane P. da Silva[13], B.Sc.; Debora C.

Nepomuceno, B.Sc.N.[13]; Rita C. C. Barbieri, B.Sc.N.[14]; Isabel K. F. M. Santos, Ph.D.[2];

Sandra R. C. Maruyama, Ph.D.[6]; Elisa M. S. Russo, Ph.D.[1]; Angelina L. Viana, Ph.D.[10];

Ana P. M. Fernandes, Ph.D.[11]; Vânia L. D. Bonato, Ph.D.[2,7]; Cristina R. B. Cardoso,

Ph.D.[1,7]†; Carlos A. Sorgi, Ph.D.[5,9]†; Marcelo Dias-Baruffi, Ph.D.[1,8]†; and Lúcia H.

Faccioli, Ph.D.[1,7]†§

*Equal contribution: Malena Martínez Pérez, Ph.D.; Vinícius Eduardo Pimentel, B. Sc;

Carlos A. Fuzo, Ph.D. and Pedro Vieira da Silva-Neto, M.Sc.

†Senior authors with equal contribution: Cristina R. B. Cardoso, Ph.D.; Carlos A.

Sorgi, Ph.D.; Marcelo Dias-Baruffi; Ph.D. and Lúcia Helena Faccioli, Ph.D.

§**Corresponding author**: Lúcia Helena Faccioli, Ph.D. (faccioli@fcfrp.usp.br)

Departamento de Análises Clínicas, Toxicológicas e Bromatológicas. Faculdade de

Ciências Farmacêuticas de Ribeirão Preto - FCFRP, Universidade de São Paulo - USP

Av. do Café, s/n - Vila Monte Alegre, Ribeirão Preto - SP, 14040-900, Ribeirão Preto,

São Paulo, Brazil. FCFRP-USP, Bloco S, Sala 96A.

1 - Departamento de Análises Clínicas, Toxicológicas e Bromatológicas. Faculdade de

Ciências Farmacêuticas de Ribeirão Preto - FCFRP, Universidade de São Paulo - USP,

Ribeirão Preto, São Paulo, Brazil;

2 - Departamento de Bioquímica e Imunologia. Faculdade de Medicina de Ribeirão Preto

- FMRP, Universidade de São Paulo-USP, São Paulo, Brazil;

3 - Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirão Preto -

FMRP, Universidade de São Paulo-USP, Ribeirão Preto, São Paulo, Brazil;

4 - Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto - FMRP,

Universidade de São Paulo-USP, São Paulo, Brazil;

5 - Departamento de Química. Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto

- FFCLRP. Universidade de São Paulo-USP, Ribeirão Preto, São Paulo, Brazil;

6 - Departamento de Genética e Evolução, Centro de Ciências Biológicas e da Saúde

Universidade Federal de São Carlos - UFSCar, São Carlos, São Paulo, Brazil;

7 - Programa de Pós-graduação em Imunologia Básica e Aplicada, Faculdade de Medicina

de Ribeirão Preto - FMRP, Universidade de São Paulo-USP, Ribeirão Preto São Paulo,

Brazil;

8 - Programa de Pós-graduação em Biociências e Biotecnologia Aplicadas à Farmácia,

Faculdade de Ciências Farmacêuticas de Ribeirão Preto - FCFRP, Universidade de São

Paulo - USP, Ribeirão Preto, São Paulo, Brazil;

9 - Programa de Pós-graduação em Imunologia Básica e Aplicada, Instituto de Ciências

Biológicas, Universidade Federal do Amazonas - UFAM, Manaus, Amazonas, Brazil;

10 - Departamento de Enfermagem Materno-Infantil e Saúde Pública, Escola de

Enfermagem de Ribeirão Preto - EERP, Universidade de São Paulo-USP, Ribeirão Preto,

São Paulo, Brazil;

11 - Departamento de Enfermagem Geral e Especializada, Escola de Enfermagem de

Ribeirão Preto - EERP, Universidade de São Paulo-USP, Ribeirão Preto, São Paulo,

Brazil;

12 - Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás -

UFG, Goiânia, Goiás, Brazil;

13 - Hospital Santa Casa de Misericórdia de Ribeirão Preto, Ribeirão Preto, São Paulo,

Brazil;

14 - Hospital São Paulo, Ribeirão Preto, São Paulo, Brazil.

Abstract

Cytokine storms and hyperinflammation, potentially controlled by glucocorticoids, occur

in COVID-19; the roles of lipid mediators and acetylcholine (ACh) and how

glucocorticoid therapy affects their release in Covid-19 remain unclear. Blood and

bronchoalveolar lavage (BAL) samples from SARS-CoV-2- and non-SARS-CoV-2-

infected subjects were collected for metabolomic/lipidomic, cytokines, soluble CD14

(sCD14), and ACh, and CD14 and CD36-expressing monocyte/macrophage

subpopulation analyses. Transcriptome reanalysis of pulmonary biopsies was performed

by assessing coexpression, differential expression, and biological networks. Correlations

of lipid mediators, sCD14, and ACh with glucocorticoid treatment were evaluated. This

study enrolled 190 participants with Covid-19 at different disease stages, 13 hospitalized

non-Covid-19 patients, and 39 healthy-participants. SARS-CoV-2 infection increased

blood levels of arachidonic acid (AA), 5-HETE, 11-HETE, sCD14, and ACh but

decreased monocyte CD14 and CD36 expression. 5-HETE, 11-HETE, cytokines, ACh,

and neutrophils were higher in BAL than in circulation (fold-change for 5-HETE 389.0;

11-HETE 13.6; ACh 18.7, neutrophil 177.5, respectively). Only AA was higher in

circulation than in BAL samples (fold-change 7.7). Results were considered significant

at $P<0.05$, 95%CI. Transcriptome data revealed a unique gene expression profile

associated with AA, 5-HETE, 11-HETE, ACh, and their receptors in Covid-19.

Glucocorticoid treatment in severe/critical cases lowered ACh without impacting disease

outcome. We first report that pulmonary inflammation and the worst outcomes in Covid-

19 are associated with high levels of ACh and lipid mediators. Glucocorticoid therapy

only reduced ACh, and we suggest that treatment may be started early, in combination

with AA metabolism inhibitors, to better benefit severe/critical patients.

Introduction

Individuals Covid-19 may present asymptomatically or with manifestations ranging from acute respiratory distress syndrome to systemic hyperinflammation and organ failure, events attributed to cytokine storms[1]. Free polyunsaturated fatty acids, such as AA and derivative eicosanoids, regulate inflammation[2,3], yet their role in Covid-19 has not been well investigated.

ACh, which is released by nerves[4], leukocytes[5], and airway epithelial cells[6], regulates metabolism[7], cardiac function[8], airway inflammation[9], and cytokine production[10], all of which occur in Covid-19. It is known that eicosanoids stimulate ACh release[3], but crosstalk between cholinergic and lipid mediator pathways in Covid-19 still need to be clarified.

In this study, levels of lipid mediators, ACh, and other inflammatory markers in blood and BAL from patients with Covid-19 who were treated or not with glucocorticoids were compared to those of non-Covid-19 and healthy-participants. Moreover, lung biopsy transcriptome reanalysis data from Covid-19 and non-Covid-19 patients corroborated our findings.

Methods

Study design and blood collection

This observational, analytic, and transversal study was conducted from June to November 2020. All participants were over 16 years old and chosen according to the inclusion and exclusion criteria described in Table S1 and in the protocol, after providing signed consent. Blood samples collected from patients positive for Covid-19 (n=190) were analyzed by RT-qPCR (Biomol OneStep/Covid-19 kit; Institute of Molecular Biology of Paraná - IBMP Curitiba/PR, Brazil) using nasopharyngeal swabs and/or

serological assays to detect IgM/IgG/IgA (SARS-CoV-2® antibody test; Guangzhou Wondfo Biotech, China). Samples obtained from a cohort of SARS-CoV-2-negative healthy participants were used as controls (n=39). Participants positive for Covid-19 were categorised as asymptomatic-mild (n=43), moderate (n=44), severe (n=54), or critical (n=49). The criteria for the clinical classification of patients were defined at the time of sample collection, as shown in Table S1. Peripheral blood samples were obtained by venous puncture from patients upon their first admission and/or during the period of hospitalisation at two medical centres, *Santa Casa de Misericordia de Ribeirão Preto* and *Hospital Sao Paulo* at Ribeirão Preto, São Paulo State, Brazil. Blood samples from healthy controls and asymptomatic-mild non-hospitalized participants were collected either at the Centre of Scientific and Technological Development "Supera Park" (Ribeirão Preto, São Paulo State, Brazil) or in the home of patients receiving at-home care. The plasma was separated from whole blood samples and stored at −80°C. For lipidomic and metabolomic analyses, 250 µL of plasma was stored immediately in methanol (1:1 *v/v*). Lipidomic and metabolomic analyses were performed by mass spectrometry (LC-MS/MS), while a cytokines, sCD14, and ACh were quantified using CBA flex Kit (flow cytometer assay) or commercial ELISA. The expression levels of CD14, CD36, CD16, and HLA-DR in cells were evaluated by flow cytometry following the gate strategy (Figure S2).

Ethical considerations

All participants provided written consent in accordance with the regulations of the *Conselho Nacional de Pesquisa em Humanos* (CONEP) and the Human Ethical Committee from *Faculdade de Ciências Farmacêuticas de Ribeirão Preto* (CEP-FCFRP-USP). The research protocol was approved and received the certificate of Presentation and Ethical Appreciation (CAAE: 30525920.7.0000.5403). The sample size was

137 determined by the convenience of sampling, availability at partner hospitals, agreement

138 to participate, and the pandemic conditions within the local community (more information

139 in the Protocol).

140 **Bronchoalveolar lavage fluid (BAL) collection and processing**

141 BAL fluids were collected from hospitalised Covid-19 patients at the severe or critical

142 stages of disease (n=32) to assess their lung immune responses. Control samples were

143 obtained from hospitalised intubated donors negative for SARS-CoV-2 (n=13) (as

144 certified by SARS-CoV-2-negative PCR), referred to as non-Covid-19 patients, who were

145 intubated because of the following primary conditions: bacterial pneumonia, abdominal

146 septic shock associated with respiratory distress syndrome, pulmonary atelectasis due to

147 phrenic nerve damage, or pulmonary tuberculosis. BAL fluid was collected as previously

148 described[11], using a siliconized polyvinylchloride catheter (Mark Med, Porto Alegre,

149 Brazil) with a closed Trach Care endotracheal suction system (Bioteque Corporation,

150 Chirurgic Fernandes Ltd., Santana Parnaíba, Brazil) and sterile 120 mL polypropylene

151 flask (Biomeg-Biotec Hospital Products Ltd., Mairiporã, Brazil) under aseptic conditions.

152 Approximately 5–10 mL of bronchoalveolar fluid was obtained and placed on ice for

153 processing within 4 h. The BAL fluids were placed into 15-mL polypropylene collection

154 tubes and received half volume of their volume of phosphate buffered saline (PBS) 0.1

155 M (2:1 *v/v*) in relation to the total volume of each sample. After centrifugation ($700 \times g$,

156 10 min), the supernatants of the BAL fluid were recovered and stored at –80°C. For

157 lipidomic and metabolomic analyses, 250 µL of these supernatants were stored

158 immediately in methanol (1:1 *v/v*). Subsequently, the remaining BAL fluid was diluted in

159 10 mL of PBS and gently filtered through a 100-µm cell strainer (Costar, Corning, NY,

160 USA) using a syringe plunger. The resulting material was used for cytokine and

161 acetylcholine (ACh) quantification. The BAL fluids were centrifuged ($700 \times g$, 10 min)

and the red blood cells were lysed using 1 mL of ammonium chloride (NH_4Cl) buffer

0.16 M for 5 min. The remaining airway cells were washed with 10 mL of PBS,

resuspended in PBS–2% heat-inactivated foetal calf serum, and counted with Trypan blue

using an automated cell counter (Countess, Thermo Fisher Scientific, Waltham, MA,

USA). The leukocyte numbers were adjusted to 1×10^9 cells/L for differential counts and

1×10^6 cells/mL for flow cytometry analysis. All procedures were performed in a Level

3 Biosafety Facility (*Departamento de Bioquímica e Imunologia, Faculdade de Medicina*

de Ribeirão Preto, Universidade de São Paulo).

Data collection

The electronic medical records of each patient were carefully reviewed. Data

included sociodemographic information, comorbidities, medical history, clinical

symptoms, routine laboratory tests, immunological tests, chest computed tomography

(CT) scans, clinical interventions, and outcomes (more information in the Protocol). The

information was documented on a standardised record form, as indicated in Tables S1,

S2, and S3. Data collection of laboratory results included first-time examinations within

24 h of admission, defined as the primary endpoint. The secondary endpoint was clinical

outcome (death or recovery).

Clinical laboratory collection

For hospitalised patients, blood examinations were performed by clinical analysis

laboratories at their respective hospitals. Blood examinations of healthy participants and

non-hospitalized patients were performed at *Serviço de Análises Clínicas* (SAC),

Departamento de Análises Clínicas, Toxicológicas e Bromatológicas of the *Faculdade*

de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão

Preto, São Paulo, Brazil. The blood samples were used to measure for liver and kidney function, myocardial enzyme spectrum, coagulation factors, red blood cells, haemoglobin, platelets, and total and differential leukocytes using automated equipment. Similarly, the absolute numbers of leukocytes in the BAL fluid were determined in a Neubauer Chamber with Turkey solution. For the counts of differential leukocytes in the BAL, 100 µL of the fluid was added to cytospin immediately after collection to avoid any interference on cell morphology. Differential leukocyte counts were conducted using an average of 200 cells after staining with Fast Panoptic (LABORCLIN; Laboratory Products Ltd, Pinhais, Brazil) and examined under an optical microscope (Zeiss EM109; Carl Zeiss AG, Oberkochen, Germany) with a $100\times$ objective (immersion oil) equipped with a Veleta CCD digital camera (Olympus Soft Imaging Solutions Gmbh, Germany) and ImageJ (1.45s) (National Institutes of Health, Rockville, MD, USA)[12]. Lymphocytes, neutrophils, eosinophils, and monocytes/macrophages were identified and morphologically characterised, and their lengths and widths were measured ($100\times$).

High-performance liquid chromatography coupled with tandem Mass Spectrometry (LC-MS/MS) assay

Reagents

Eicosanoids, free fatty acids (AA, EPA, and DHA), and metabolites as molecular weight standards (MWS) and deuterated internal standards were purchased from Cayman Chemical Co. (Ann Arbor, MI, USA). HPLC-grade acetonitrile (ACN), methanol (MeOH), and isopropanol were purchased from Merck (Kenilworth, NJ, USA). Ultrapure deionised water (H_2O) was obtained using a Milli-Q water purification system (Merck-Millipore, Kenilworth, NJ, USA). Acetic acid (CH_3COOH) and ammonium hydroxide (NH_4OH) were obtained from Sigma Aldrich (St. Louis, MO, USA).

Sample preparation and extraction

The plasma (250 μL) in EDTA-containing tubes (Vacutainer® EDTA K2; BD

Diagnostics, Franklin Lakes, NJ, USA) and BAL (250 μL) samples were stored in MeOH

(1:1, *v/v*) at –80°C. Three additional volumes of ice-cold absolute MeOH were added to

each sample overnight at –20°C for protein denaturation and after lipid solid-phase

extraction (SPE). To each sample, 10 μL of internal standard (IS) solution was added,

centrifuged at $800 \times g$ for 10 min at 4°C. The resulting supernatants were collected and

diluted with deionised water (ultrapure water; Merck-Millipore, Kenilworth, NJ, USA) to

obtain a MeOH concentration of 10% (*v/v*). In the SPE extractions, a Hypersep C18-500

mg column (3 mL) (Thermo Scientific-Bellefonte, PA, USA) equipped with an extraction

manifold collector (Waters-Milford, MA, USA) was used. The diluted samples were

loaded into the pre-equilibrated column and washing using 2 mL of MeOH and H_2O

containing 0.1% acetic acid, respectively. Then, the cartridges were flushed with 4 mL of

H_2O containing 0.1% acetic acid to remove hydrophilic impurities. The lipids that had

been adsorbed on the SPE sorbent were eluted with 1 mL of MeOH containing 0.1%

acetic acid. The eluates solvent was removed in vacuum (Concentrator Plus, Eppendorf,

Germany) at room temperature and reconstituted in 50 μL of MeOH/H2O (7:3, *v/v*) for

LC-MS/MS analysis.

LC-MS/MS analysis and lipids data processing

Liquid chromatography was performed using an Ascentis Express C18 column

(Supelco, St. Louis, MO, USA) with 100×4.6 mm and a particle size of 2.7 μm in a high-

performance liquid chromatography (HPLC) system (Nexera X2; Shimadzu, Kyoto,

Japan). Then, 20 μL of extracted sample was injected into the HPLC column. Elution was

carried out under a binary gradient system consisting of Phase A, comprised of H_2O,

ACN, and acetic acid (69.98:30:0.02, *v/v/v*) at pH 5.8 (adjusted with NH_4OH), and Phase

B, comprised of ACN and isopropanol (70:30, *v/v*). Gradient elution was performed for

25 min at a flow rate of 0.5 mL/min. The gradient conditions were as follows: 0 to 2 min,

0% B; 2 to 5 min, 15% B; 5 to 8 min, 20% B; 8 to 11 min, 35% B; 11 to 15 min, 70% B;

and 15 to 19 min, 100% B. At 19 min, the gradient was returned to the initial condition

of 0% B, and the column was re-equilibrated until 25 min. During analysis, the column

samples were maintained at 25°C and 4°C in the auto-sampler. The HPLC system was

directly connected to a TripleTOF 5600+ mass spectrometer (SCIEX-Foster, CA, USA).

An electrospray ionisation source (ESI) in negative ion mode was used for high-resolution

multiple-reaction monitoring (MRM[HR]) scanning. An atmospheric-pressure chemical

ionisation probe (APCI) was used for external calibrations of the calibrated delivery

system (CDS). Automatic mass calibration (<2 ppm) was performed periodically after

each of the five sample injections using APCI Negative Calibration Solution (Sciex-

Foster, CA, USA) injected via direct infusion at a flow rate of 300 μL/min. Additional

instrumental parameters were as follows: nebuliser gas (GS1), 50 psi; turbo gas (GS2),

50 psi; curtain gas (CUR), 25 psi; electrospray voltage (ISVF), –4.0 kV; temperature of

the turbo ion spray source, 550°C. The dwell time was 10 ms, and a mass resolution of

35,000 was achieved at *m/z* 400. Data acquisition was performed using Analyst[TM]

software (SCIEX- Foster, CA, USA). Qualitative identification of the lipid species was

performed using PeakView[TM] (SCIEX-Foster, CA, USA). MultiQuant[TM] (SCIEX-Foster,

CA, USA) was used for the quantitative analysis, which allows the normalisation of the

peak intensities of individual molecular ions using an internal standard for each class of

lipid. The quantification of each compound was performed using internal standards and

calibration curves, and the specific mass transitions of each lipid were determined

according to our previously published method[13]. The final concentration of lipids was

normalised by the initial volume of plasma or BAL fluid (ng/mL).

Metabolomics analysis

Metabolite was extracted and samples were transferred to autosampler vials for

LC–MS analysis using TripleTOF5600+ Mass Spectrometer (Sciex-Foster, CA, USA)

coupled to an ultra-high-performance liquid chromatography (UHPLC) system (Nexera

X2; Shimadzu, Kyoto, Japan). Reverse-phase chromatography was performed similarly

to lipids analyses above. Mass spectral data were acquired with negative electrospray

ionisation, and the full scan of mass-to-charge ratio (*m/z*) ranged from 100 to 1500.

Proteowizard software[14] was used to convert the wiff files into *mz* XML files. Peak

peaking, noise filtering, retention time, *m/z* alignment, and feature quantification were

performed using apLCMS[15]. Three parameters were used to define a metabolite feature:

mass-to-charge ratio (*m/z*), retention time (min), and intensity values. Data were $\log_2$

transformed and only features detected in at least 50% of samples from one group were

used in further analyses. Missing values were imputed using half the mean of the feature

across all samples. Mummichog (version 2) was used for metabolic pathway enrichment

analysis (mass accuracy under 10 ppm)[16].

Acetylcholine measurement

ACh was measured in heparinized plasma (SST® Gel Advance®; BD Diagnostics,

Franklin Lakes, NJ, USA) and in BAL using a commercially available

immunofluorescence kit (ab65345; Abcam, Cambridge, UK) according to the

manufacturer's instructions. Briefly, ACh was converted to choline by adding the enzyme

acetylcholinesterase to the reaction, which allows for total and free-choline measurement.

The amount of ACh present in the samples was calculated by subtracting the free choline

from the total choline. The products formed in the assay react with the choline probe and

can be measured by fluorescence with excitation and emission wavelengths of 535 and

587 nm, respectively (Paradigm Plate Reader; SpectraMax, San Diego, CA, USA). The

concentration of ACh was analysed using SoftMax® software (SpectraMax, Molecular

Devices, Sunnyvale, CA, USA), expressed as $pmol.mL^{-1}$.

286 Soluble CD14 (sCD14) measurement

287 Samples from heparinized plasma (SST® Gel Advance®; BD Biosciences, Franklin

288 Lakes, NJ, USA) were placed in 96-well plates. The concentration of sCD14 was

289 determined using an ELISA kit (DY383; R&D Systems, Minneapolis, MN, USA),

290 following the manufacturer's instructions, expressed as $pg.mL^{-1}$.

291 Flow Cytometry

Uncoagulated blood samples in EDTA-containing tubes (Vacutainer® EDTA K2; BD

Biosciences) were processed for flow cytometry analysis of circulating leukocytes.

Whole blood (1 mL) was separated and red blood cells were lysed using RBC lysis buffer

(Roche Diagnostics GmbH, Mannheim, GR). Leukocytes were washed in PBS containing

5% foetal bovine serum (FBS) (Gibco™, USA), centrifuged, and resuspended in Hank's

balanced salt solution (Sigma-Aldrich, Merck, Darmstadt, Germany) containing 5% FBS,

followed by surface antigen staining. Similarly, cells obtained from BAL fluid were

processed for flow cytometry assays. Briefly, cells were stained with Fixable Viability

Stain 620 (1:1000) (BD Biosciences) and incubated with monoclonal antibodies specific

for CD14 (1:100) (M5E2; Biolegend), HLA-DR (1:100) (G46-6; BD Biosciences), CD16

(1:100) (3G8; Biolegend), and CD36 (1:100) (CB38, BD Biosciences) for 30 min at 4°C.

Stained cells were washed and fixed with BD Cytofix™ Fixation Buffer (554655; BD

Biosciences, San Diego, CA, USA). Data acquisition was performed using a LSR-

Fortessa™ flow cytometer (BD Biosciences, San Jose, CA, USA) and FACS-Diva

software (version 8.0.1) (BD Biosciences, Franklin Lakes, NJ, USA). For the analysis,

300,000 events were acquired for each sample. Data were evaluated using FlowJo®

software (version 10.7.0) (Tree Star, Ashland, OR, USA) to calculate the cell frequency,

dimensionality reduction, and visualisation using t-distributed stochastic neighbour

embedding. Gate strategy performed as described before [17], as shown in Figure S2.

Cytokine Measurements

The cytokines interleukin (IL)-6, IL-8, IL-1ß, IL-10, and tumour necrosis factor

(TNF) were quantified in heparinized plasma and BAL fluid samples using a BD

Cytometric Bead Array (CBA) Human Inflammatory Kit (BD Biosciences, San Jose, CA,

USA), according to manufacturer's instructions. Briefly, after sample processing, the

cytokine beads were counted using a flow cytometer (FACS Canto TM II; BD

Biosciences, San Diego, CA, USA), and analyses were performed using FCAP Array

(3.0) software (BD Biosciences, San Jose, CA, USA). The concentrations of cytokines

were expressed as pg.mL^{-1}.

Re-analysis of transcriptome data from lung biopsies of patients with Covid-19

To gain a better understanding of the correlation between the altered concentrations

of ACh, AA, and AA-metabolites detected in the plasma and BAL fluid of severe/critical

Covid-19 patients, we performed a new analysis by re-using a previously published

transcriptome open dataset [18], deposited in the Gene Expression Omnibus repository

under accession no. GSE150316 [19]. We used transcriptome data from lung samples

(n=46) from patients with Covid-19 (n=15), seven of which displayed a low viral load

and eight a high viral load, and non-Covid-19 patients (n=5) with other pulmonary

illnesses (negative control). Patients with a high viral load had meantime periods of

hospital stays (3.6±2.2 days) and duration of illness (7.2±3.02 days) shorter than the

patients with low viral load (14±7.9 and 19±4.9 days, respectively), as described by the

authors of the public data source [18]. Hence, for analysis purposes, all patient samples were

grouped into four classifications: Covid-19 (CV), Covid-19 low viral load (CVL), Covid-

19 high viral load (CVH), and non-Covid-19 (NCV). The strategy for reanalysing the

transcriptome was implemented according to three consecutive steps: (i) co-expression

analysis, (ii) differential expression analysis, and (iii) biological network construction.

Initially, for the co-expression study, normalised transcriptome data in $\log_2$ of reads per

million (RPM) were filtered by excluding non-zero counts in at least 20% of the samples.

Next, the selected genes were explored in the R package Co-Expression Modules

identification Tool (CEMITool) [20], using a p-value of 0.05 as the threshold for filtering.

Then, the co-expression modules were analysed for the occurrence of ACh and AA genes

list obtained from the Reactome pathways [21], as well as the Covid-19-related genes

obtained from the literature (Supplementary Appendix I). Next, differential gene

expression between samples from the lung biopsy transcriptome (CV, NCV, CVL, and

CVH) was measured using the DESeq2 package [22], with p-values adjusted using the

Benjamini and Hochberg method [23]. The list of differentially express genes (DEGs)

generated for all comparisons was filtered from the genes listed in Supplementary

Appendix I, considering the values of $\log_2$ of fold-change (FC) greater than 1

($|\log2(FC)|>1$) and adjusted $p<0.05$. Finally, a first-order biological network was

constructed using co-expression module(s) containing genes associated with the ACh and

AA pathways to characterise the interplay between these mediators in combination with

Covid-19 severity markers, as well as to identify relevant DEGs and hub genes in this

network, using the BioGRID repository [24]. The networks were constructed, analysed, and

graphically represented using the R packages igraph [25], Intergraph [26], and ggnetwork [27].

Due to the substantial influence of glucocorticoid treatment on the levels of some

mediators, we measured the sensitivity of genes from the differential expression analysis

between CV samples from patients who underwent treatment (CTC, three patients and

ten samples) and patients who were not treated (NCTC, 12 patients and 36 samples), as

previously described [18].

Statistical Analysis

Two-tailed tests were used for the statistical analysis, with a significance value of

$p < 0.05$ and a confidence interval of 95%. The data were evaluated for a normal

distribution using the Kolmogorov–Smirnov test. The parametric data were analysed

using unpaired t-tests (for two groups) or one-way ANOVA followed by Tukey's multiple

comparison tests for three or more groups simultaneously. For data that did not display a

Gaussian distribution, Mann-Whitney (for two-group comparisons) or Kruskal-Wallis

testes were used, followed by Dunn's post-tests for analysis among three or more groups.

The cytokine network data in patients with Covid-19 were analysed using significant

Spearman's correlations at $p<0.05$. Data were represented by connecting edges to

highlight positive strong ($r \geq 0.68$; thick continuous line), moderate ($0.36 \geq r < 0.68$;

thinner continuous line), or weak ($0 > r < 0.36$; thin continuous line) and negative strong

($r \leq -0.68$; thick dashed line), moderate ($-0.68 > r \leq -0.36$; thinner dashed line), or weak

($-0.36 < r > 0$; thin dashed line), as proposed previously [28,29]. The absence of a line

indicates the non-existence of the relationship. The Venn diagrams were elaborated using

the online tool Draw Venn Diagram (http://bioinformatics.psb.ugent.be/webtools/Venn/).

The results were tabulated using GraphPad Prism software (version 8.0) and the

differences were considered statistically significant at $p<0.05$. See the Additional

Statistical Report section for more information. Some of the confounding variables

associated with Covid-19 (age, sex, obesity, hypertension, and diabetes mellitus) were

analysed for their potential impacts on the main analytical procedures of this study, such

as ACh, AA, 5-HETE, and 11- HETE measurements of the plasma (healthy,

asymptomatic-to-mild, moderate, severe, and critical patients) and BAL (severe and

critical patients) samples. This analysis was performed using the Kruskal-Wallis, Mann-

Whitney, Spearman's correlation, or Chi-square ($\chi2$) tests (Table S7-S9).

Results

Study Population

386   This study enrolled 39 healthy-participants, 13 hospitalized non-Covid-19, and

387   190 Covid-19 patients aged 16-96 years from April to November 2020. The 190 Covid-

388   19 patients were categorized as having asymptomatic-to-mild (n=43), moderate (n=44),

389   severe (n=54), or critical (n=49) disease (Table S2).

Covid-19 Modifies Circulating Soluble Mediators and Cell Populations

To determine whether SARS-CoV-2 infection alters the metabolism of lipid

mediators, we used high-resolution sensitive mass spectrometry to perform targeted

eicosanoid analysis and nontargeted metabolomics using plasma from healthy-

participants and Covid-19 patients. In total, 8,791 metabolite features were present in at

least 50% of all samples, and the relative abundance of 595 metabolite features (FDR

adjusted P<0.05) was altered in the groups studied (Figure 1A). Two-way hierarchical

clustering based on these significant metabolite features resulted in three clear clusters:

one for severe/critical Covid-19 patients, one for healthy-participants and one for

asymptomatic-to-mild and moderate Covid-19 (Figure S1A). Pathway analysis revealed

the top significant metabolic pathways to be enriched in features involved in fatty acid

biosynthesis, metabolism, activation, and oxidation (Figure 1B). Compared to healthy-

participants, tentative metabolite annotations suggested an increased abundance of fatty

acids (FFAs), such as linoleic acid, tetradecanoate, dodecanoate and AA, in COVID-19

(Figure 4C-F). Among the identified lipids, AA was the most abundant, and its levels

correlated with the severity of Covid-19 (Figure 1F). Linoleic acid can be metabolized to

AA, which in turn is a substrate for eicosanoids, such as 5-hydroxyeicosatetraenoic acid

(5-HETE) and 11-hydroxyeicosatetraenoic acid (11-HETE) (Figure 1G, 1H); both

molecules with function in the immune response. Overall, the increased plasma levels of

AA in Covid-19 indicate that it predicts disease severity.

As eicosanoids induce cell recruitment and regulate immune responses, we next

determined the profile of immune cells and soluble mediators in whole blood and plasma

of patients with Covid-19 and healthy-participants. According to whole-blood analysis,

absolute leukocyte and neutrophil counts (Figure 2A, 2B) were significantly higher but

lymphocyte counts (Figure 2C) significantly lower in patients with severe/critical disease

than in those with moderate disease. Eosinophil (Figure 2D) and basophil counts (Figure

2E) were reduced severe disease compared to asymptomatic and moderate disease.

Although no differences in total monocyte counts among the groups (Figure 2F)

were observed based on CD16, CD14 and HLA-DR, expression of membrane CD14 was

reduced in all SARS-CoV-2-infected patients compared to healthy-participants (Figure

2G; Figure S2, S3). In parallel, CD36 expression was decreased in monocytes from

patients with severe/critical disease (Figure 2H), but sCD14 was increased only in plasma

from critical patients (Figure 2I). We did not detect differences in classic or non-classic

monocytes, but the percentage of intermediate monocytes was decreased in all SARS-

CoV-2-infected participants compared to healthy-participants (Figure 2J, 2K, 2L). Based

on plasma cytokine level analysis, patients with moderate, severe, and critical disease

share a Covid-19 cytokine profile defined by increased IL-8, IL-6, and IL-10 (Figure 2M,

2N, 2Q) levels, with unaltered IL-1β and TNF levels (Figure 2O, 2P).

Covid-19 Induces Strong Lung Responses

We performed measurements of BAL from hospitalized Covid-19 and non-

Covid-19 patients. Changes in lung metabolomics induced by SARS-CoV-2 infection

(Figure 3A; Figure S1B) included alterations in sphingolipids, beta oxidation of

trihydroxyprostanoil-CoA, biosynthesis and metabolism of steroidal hormones, vitamin

D3, and glycerophospholipids (Figure 3B). We also evaluated AA and its metabolites.

Despite no differences in AA, levels of 5-HETE and 11-HETE in BAL were significantly

higher in Covid-19 than in non-Covid-19 patients, though other metabolites did not differ

between these groups (Figure 3C). When assessing leukocytes in BAL between the

patient groups, we found no differences in total or differential counts, with the exception

of lymphocyte numbers (Figure 3D, 3E). In contrast to eicosanoids, cytokine profiles in

Covid-19 and non-Covid-19 patients were similar (Figure 3F), suggesting that lipid

mediators contribute to the pathophysiological processes induced by SARS-CoV-2.

Interestingly, we observed a significant reduction in classical (Figure 3G) and

intermediate (Figure 3H) monocytes in BAL from Covid-19 patients. In parallel, CD14

and CD36 expression in monocyte was lower in BAL of Covid-19 than in that of non-

Covid-19 patients (Figure 3I, 3J).

Acetylcholine, Cytokines and Eicosanoids are Higher in the Lung Micro-
Environment

447   We compared systemic and lung responses only in patients with severe/critical

448   Covid-19 and found significantly higher levels of cytokines in BAL than in blood (Figure

449   4A). When comparing lipid mediator levels in either compartment from the same Covid-

19 patients, we detected lower AA but higher levels of 5-HETE and 11-HETE in BAL than in blood (Figure 4B, 4C, 4D). Previous results from our group[3] have shown that eicosanoids contribute to ACh release. Therefore, we next measured ACh in patients with Covid-19 and observed higher plasma levels of ACh in patients with Covid-19; in addition, ACh was elevated in patients with severe/critical disease compared with those with asymptomatic/moderate disease or healthy-participants (Figure 4E). Unexpectedly, in patients with severe/critical Covid-19, ACh levels in BAL were 10-fold higher than those in serum, and patients treated with glucocorticoids showed decreases in ACh in both compartments (Figure 4F, 4G). Interesting, neutrophil counts were higher in BAL, as these cells produce high levels of 5-HETE and IL-1β, both of which are mediators of ACh release[30,31] (Figure 4H). Correlation analysis was then performed to evaluate the relationship between eicosanoids, cytokines, sCD14 and ACh in patients with Covid-19. When comparing blood samples from all patients, we detected strong correlations between ACh *versus* IL-1β and moderate correlations between ACh *versus* AA. A substantial number of interactions between AA and its metabolites and between cytokines and eicosanoids were observed (Figure 4I; Figure S4A). Correlations among all parameters were also observed in BAL (Figure 4J; Figure S4B). To evaluate the benefit of glucocorticoid treatments and their relationship with eicosanoids, CD14 and ACh, we analysed the intersections in a Venn diagram of blood and BAL from severe/critical Covid-19. The results showed that treatment of Covid-19 with glucocorticoids did not have a significant influence on eicosanoid or sCD14 release in patients with more severe stages of disease; in critical patients, however, reductions of 44% and 65% in ACh levels in blood and BAL, respectively, were observed (Figure 4K-4Q; Figure S5). These findings suggest that the use of glucocorticoids has a positive effect on resolution of the

474   inflammatory process because they reduce ACh release, which directly or indirectly

475   stimulates cell recruitment and proinflammatory mediator release.

476   Altered Expression of Acetylcholine and Arachidonic Acid Pathway Genes in Lung

477   Biopsies From Some Covid-19 Patients

In this study, we reanalysed the lung biopsy transcriptome from Covid-19 patients

to evaluate expression of ACh and AA pathway genes (Supplementary Appendix I).

These genes were coexpressed only in a single module (M1) that included genes related

to the ACh release cycle, AA metabolism, cholinergic and eicosanoid receptors, and

biomarkers of Covid-19 severity (Figure 5A; Table S4; Supplementary Appendix II).

Furthermore, expression of nearly all genes was upregulated in some deceased Covid-19

patients with long hospital stays and low viral loads (Figure 5B; Figure S6A;

Supplementary Appendix III). These differentially expressed genes populated the

biological network and are likely under the action of some hubs (Figure 5C;

Supplementary Appendix IV), such as oestrogen receptor II (ESR2) and albumin (ALB).

We identified a unique proinflammatory gene expression profile in lung biopsies related

to cholinergic and eicosanoid receptors (Figure 5H, 5I; Figure S6B, S6C). In combination

with the altered levels of ACh, AA, and AA metabolites found in patient from our cohort,

the transcriptome data reported herein strengthen the likelihood that these mediators

contribute to Covid-19 severity (Figure 5D-5G). Interestingly, lung samples from Covid-

19 patients with short hospital stays and high viral loads did not present this unique

expression profile of ACh or AA pathway genes (Figure 5H, 5I; Figure S6B, S6C). Some

Covid-19 patients treated versus not with glucocorticoid showed transcript expression of

monoglyceride lipase (MGLL) and N-acylethanolamine acid amidase (NAAA) and up-

regulation of fatty acid amide hydrolase (FAAH), which are involved in the production

of AA from endocannabinoid (cases 3, 9, and 11; Figure 5B; Supplementary Appendix

III). Besides, we detected other DEGs in biopsy samples from Covid-19 patients

(glucocorticoid-treated versus non-treated) associated with AA, ACh, interferon

pathways, and Covid-19 biomarkers (Supplementary Appendix III).

Discussion

A consensus is building around the fatal effects of SARS-CoV-2 infection, which is

increasingly believed to cause death as a result of systemic hyperinflammation and multi-

organ collapse[32], secondary to systemic cytokine storms [33–35]. However, few studies have

compared pulmonary and systemic inflammation [36] or considered the contribution of

eicosanoids and neurotransmitters to these effects. In our study, we hypothesised that, in

Covid-19, pulmonary cells and leukocytes, in addition to cytokines, release eicosanoids

and ACh, mediating local and systemic manifestations. In patients with severe/critical

SARS-CoV-2 infection, we found that ACh, 5-HETE, 11-HETE, and cytokines were

more abundant in the lung than under systemic conditions. In contrast, only the levels of

AA were found to be higher in the circulation than in the BAL fluid. Interestingly, in

patients with severe/critical disease who were treated with corticosteroids, only ACh was

inhibited.

In our study, we compared the lung and systemic responses in association with the

lung transcriptome and demonstrated a robust correlation between lipid mediators,

neurotransmitters, and their receptors in SARS-CoV-2 infection. However, contrary to

what has been suggested by previous studies [37,38], only small amounts of eicosanoids were

found in the plasma of patients with severe/critical disease, with significant differences

observed only in AA, 5-HETE, and 11-HETE. Interestingly, the levels of 5-HETE and

11-HETE were found to be remarkably higher in BAL, as well as AA in plasma,

suggesting that AA and its metabolites mediate responses to Covid-19. 5-HETE induces

neutrophil recruitment [39], pulmonary oedema [40], and ACh release [30]. It is released by

human neutrophils, and its esterified form promotes IL-8 secretion [31]. Unlike the

esterified form [31], free-5-HETE did not inhibit NETs formation, a key event in Covid-19

[41]. Remarkably, 11-HETE originating from monocytes/macrophages [42], endothelial cells

[43], and platelets [44] is induced by hypoxia [45], IL-1β [46], contributes to ACh functions [43], and

inhibits insulin release [47]. The involvement of AA was confirmed by bioinformatic

analyses that identified the expression or upregulation of genes related to AA metabolism

and eicosanoid receptors in some lung biopsies. These included the OXER1 gene, which

encodes a receptor for AA and 5-HETE [48] which mediates neutrophil

activation/recruitment [49,50]. Our metabolomic analysis also showed an increase in the

plasma AA and linoleic acid levels, similar to a plasma lipidome performed by Schwarz

et al., suggesting a strong correlation between lipid mediators and Covid-19 severity [51].

Accordingly, the ELOVL2 gene, which is involved in linoleic acid metabolism and AA

synthesis [52], was upregulated in lung biopsies.

The RNA expression of ALOX5, an enzyme that participates in lipid mediator

production, is upregulated in some immune cell types from severe Covid-19 patients [53],

and has been detected in the lung biopsies of deceased Covid-19 patients [18]. In contrast

to our lung transcriptome re-analysis findings, the expression of cytochrome p450 (CYP)

enzymes, which are also involved in lipid mediator generation, was not detected in the

peripheral blood mononuclear cells (PBMC) transcriptome re-analysis from severe

Covid-19 patients [53]. One possible explanation for this contradiction is that Covid-19 is a

heterogeneous illness composed of distinct tissue gene expression associated with Covid-

19 severity and different immunopathological profiles in infected tissues [18,54]. This

immunological heterogeneity could be related to two types of evolution of severe Covid-

19 patients, one associated with a high viral load and susceptibility to SARS-CoV-2

infection, a shorter hospitalisation time, and exudative diffuse alveolar damage, and

another associated with a low or undetectable viral load, a mixed lung histopathological

profile, and a longer hospitalisation time associated with non-homeostatic pulmonary

inflammation [18,54,55]. In this context, we found that the expression levels of some lipid

mediators and ACh and AA pathway genes varied in the plasma and BAL samples of

severe/critical patients, which were found to be preferentially activated in the lungs of

deceased Covid-19 patients with low viral loads, long hospitalisation times, and

damaging lung inflammation.

Nevertheless, it remains unclear whether AA and linoleic acid contribute to host

protection [56] and tissue damage, or whether they represent a viral escape mechanism. AA

is known to directly interact with the virus, reducing its viability and inducing membrane

disturbances, disfavouring SARS-CoV-2 entry [57–59]. On the other hand, reduced plasma

AA levels may be associated with lung injury and poor outcomes in Covid-19 infection

[60]. Within this context, Shen and et al. found lower concentrations of AA in survivors of

severe Covid-19 infection [37]. However, in the present study, the levels of AA were found

to be increased in the plasma of patients who died from severe Covid-19, suggesting that

the potential benefits of AA are overcome by a higher production of its proinflammatory

metabolites, 5-HETE and 11-HETE. Interestingly, in our cohort, AA, 5-HETE, and 11-

HETE were not altered in the plasma or BAL fluid of patients with severe/critical Covid-

19 infection who had received glucocorticoid treatment. This may be explained by the

fact that AA, in addition to calcium-activated-PLA_2 [61] also originates from

glucocorticoid-insensitive phospholipase [62], adipocyte destruction [63], linoleic acid [64], or

the degradation of endocannabinoids by FAAH [65], a macrophage enzyme detected in

SARS-CoV-2-infected patients [66]. Notably, some CVL Covid-19 patients, regardless of

whether they were treated or not with glucocorticoids, showed transcript expression of

MGLL and NAAA, as well as an up-regulation of FAAH and all of the enzymes involved

in the production of AA from endocannabinoid [67]. In addition, we detected other DEGs

in biopsy samples (glucocorticoid-treated versus non-treated) associated with AA, ACh,

interferon pathways, and Covid-19 biomarkers. Glucocorticoids have been used widely

to reduce the morbidity and mortality rates of Covid-19 patients, but have not been

effective for all patients [68]. The mortality rate for glucocorticoid-treated hospitalised

Covid-19 patients from our cohort was higher than that reported in the RECOVERY trial

and similar to that described in the CoDEX trial conducted in Brazil [69]. High mortality

rates could be associated with several factors, including a low mean $PaO_2:FiO_2$ ratio and

overloaded public health systems in countries with limited resources, such as Brazil [69]

and as well as glucocorticoid dose, initiation, and duration of therapy [70,71]. In addition,

the precise threshold at which a patient should be treated with glucocorticoids, that is to

avoid the manifestation of adverse effects associated with comorbidities and inefficient

clearance of SARS-CoV-2, remains unclear [72]. However, a delayed start of glucocorticoid

therapy could result in a lack of response due to patients reaching a point of no return, as

suggested previously by our research group with regards to scorpion poisoning, which

triggers a sterile inflammatory process [3]. On the other hand, considering that Covid-19 is

a non-sterile hyperinflammatory disease, the administration of glucocorticoids is more

effective after the initial phase in which hospitalised patients have low or undetectable

viral loads [18,68]. Our data suggest that SARS-CoV-2 infection activates the glucocorticoid-

insensitive release of AA metabolites associated with Covid-19 severity. Hence, lipid

mediator production pathways could be important molecular targets for Covid-19

treatment, as suggested by other researchers [53]. Accordingly, we suggested that, in order

to improve the benefits of glucocorticoid therapy in hospitalized patients, who show

lower or undetectable viral loads, patients should be treated as soon as possible in

combination with AA metabolism inhibitors.

CD36 is expressed in several cells [73,74], where it induces Ca^{++} mobilisation, cell

signalling, LTB_4 production, and cellular fatty acid uptake [75–78]. The maintenance of high

free-AA levels in patients with severe/critical glucocorticoid-treated disease may result

from the reduction of CD36 on macrophage membranes. Intriguingly, CD36 is a gustatory

lipid sensor [79], whose deficit in cell membranes may account for the symptoms of ageusia,

anosmia, diarrhoea, hyperglycaemia, platelet aggregation, and cardiovascular

disturbances experienced by Covid-19 patients [75–77]. CD36 is a substrate of matrix

metalloproteinase-9 (MMP-9) and disintegrin metalloproteinase domain-containing

protein 17 (ADAM17) [80,81]. Decreased CD36 expression in Covid-19 patients most likely

results from the action of these enzymes. MMP-9 is produced by neutrophils [82], induced

by TNF-α [83], unaffected by glucocorticoids, and associated with respiratory syndrome in

Covid-19 [84]. ADAM17 has been described as a target for Covid-19 treatment [85].

In agreement with previous reports [1,34,86,87], in the present study, high

concentrations of IL-6, IL-8, and IL-10 were detected, along with insignificant levels of

IL-1β in plasma. In contrast, the inflammatory cytokine TNF-α was found at the lowest

concentration in BAL fluid, and insignificant levels were detected in the blood. The low

levels of TNF-α production are correlated with the decreased counts of intermediate

monocytes in the blood and BAL, which are major sources of this cytokine [88]. As

expected, in the BAL from patients with severe/critical Covid-19, the levels of IL-8, IL-

6, IL-1β, TNF-α, and IL-10 were significantly higher compared with the plasma of all

participants, or when paired with patients' own plasma. Notably, in BAL, the most

abundant cytokine was IL-8, which is produced by neutrophils [89], lung macrophages [90],

and bronchial epithelial cells [10], and is induced by 5-HETE [31] and ACh [10]. Interestingly,

BAL fluid from non-Covid-19 patients also presented a high concentration of cytokines

that did not differ from that of patients with Covid-19. This suggests that cytokine storms

are not a key differential factor in this disease. Contrary to our expectations,

glucocorticoids did not alter cytokine production (Table S7). As a result, we suggest that,

regardless of whether Covid-19 is treated with glucocorticoids, cross-talk occurs between

cytokines, lipid mediators, and ACh, as previously reported [2,3,91]. IL-1β induces 11-HETE

[46]; arterial relaxation induced by ACh is mediated by 11-HETE and is inhibited by

indomethacin [43]. In our studies on scorpion envenomation, ACh release was found to be

mediated by PGE_2-induced by IL-1β and inhibited by indomethacin [3]. In the present

study, comparing AA, 5-HETE, 11-HETE, cytokine, and receptor expression

demonstrated the absence of glucocorticoid effects. These results, in addition to the

results of other studies from our laboratory [3], suggest that glucocorticoids did not have an

effect in our cohort. This was most likely due to the fact that treatment was started late,

namely after inflammation has been triggered by infection. In this context, Covid-19

patients could had already reached the point of no return, similar to what has been

previously described in scorpion envenomation [3].

As predicted by Virgilis and Giovani [92], neurotransmitters are produced in Covid-

19. ACh induces mucus secretion, bronchoconstriction, lung inflammation and

remodelling [9], cardiac dysfunction in scorpionism [3], NETs formation [93], IL-8 release [10],

thrombosis [94], and obesity-related severity [95]. In addition to the nervous system [4], ACh is

also produced by pulmonary vessels [96], airway epithelial cells [6], and immune cells [5]. When

binding to anti-inflammatory neural nicotinic receptors induces AA release [97], it inhibits

nicotine receptors [97], which are highly expressed in lungs [98]. In our cohort, a correlation

between the AA and ACh levels and the severity of Covid-19 infection was observed,

which was reinforced by the results of our bioinformatics study. Our lung transcriptome

re-analyses showed that ACh release cycle genes were activated, including acetylcholine-

synaptic release (synaptotagmin 1) and neuronal choline transporter (Solute Carrier

Family 5 Member 7, SLC5A7). Accordingly, SLC5A7 gene expression was higher in the

lung of patients who died from Covid-19 infection than patients who survived [99]. Because

this gene mediates the translocation of choline into lung epithelial cells [100] and

macrophages [101], the production of ACh in BAL may also depend on non-neuronal cells.

Indeed, the ACh repressor gene in non-neural cells (RE1 Silencing Transcription Factor)

is reduced in the lungs of patients who died of Covid-19 [99]. The activation of T-

lymphocyte EP4 induces the release of ACh [102], suggesting that AA metabolites

contribute to the release of ACh from lung and immune cells. As expected, ACh

production in patients with severe/critical disease was found to be inhibited by

glucocorticoids, since this drug blocks ACh production by lung epithelial cells [103–105].

Patients with Covid-19 (mostly methylprednisolone-treated patients) showed lower

plasma levels of choline and higher plasma levels of phosphocholine [37]. In addition, a

distinct pattern of ACh receptor mRNA expression was found in patients who died of

Covid-19 (mainly in the CVL-lengthy hospital stay group). This profile is characterised

by low levels of expression of the nicotinic receptor encoded by cholinergic receptor

nicotinic alpha 7 subunit gene (CHRNA7) and increased levels of expression of two

nicotinic and one muscarinic receptor in deceased-CVL compared to deceased non-

Covid-19 patients. These proteins are encoded by the cholinergic nicotinic alpha 3 subunit

gene (CHRNA3), the cholinergic nicotinic receptor 5 subunit gene (CHRNA5), and the

muscarinic cholinergic receptor 3 gene (CHRM3), respectively. These three upregulated

genes were also co-expressed and associated with pulmonary inflammatory disorders

[9,106–110]. Notably, SARS-CoV-2 spike glycoprotein interacts with the α7 nicotinic

acetylcholine receptor, which may compromise the cholinergic anti-inflammatory

pathway[111].

The ACh-nicotinic receptor, encoded by CHRNA7, is expressed in various lung

cells and macrophages [112]. It displays extensive anti-inflammatory activities, including

the inhibition of pro-inflammatory cytokine production [113], the recruitment of neutrophils

[114], and the reduction of CD14 expression in human monocytes [115]. The increased degrees

of inflammation in the BAL fluid of patients with severe/critical Covid-19 may be

associated with the lower levels of anti-inflammatory CHRNA7 expression. However, a

reduction in monocyte CD14 may result from high levels of IL-6 production [116], since the

levels of CHRNA7 expression were very low. Interestingly, the ACh-M3 receptor in

immune cells has been found to be up-regulated by ACh, which mediates its pro-

inflammatory actions, including the production of IL-8 and the recruitment of neutrophils

[117]. Furthermore, the interaction between ACh and its receptor triggers the AA-derived

release of eicosanoids, including 5-HETE [97,118,119]. Remarkably, vitamin D modulates the

ACh-M3 receptor [120], which may explain its beneficial effects in the prevention of Covid-

19 [121]. Based on the anti-inflammatory effects of nicotinic receptors and the

downregulation of the SARS-CoV-2 receptor ACE2 promoted by nicotine, therapies

involving nicotinic receptors have been proposed to treat Covid-19 infection [122,123]. In

fact, based on these findings, an acetylcholinesterase inhibitor [124,125] and a nicotinic

receptor agonist have been tested [126,127]. However, recent studies have demonstrated that

nicotine and smoking increase ACE2 receptor density [128,129], and that the potential

beneficial effects of nicotine were restricted to a small group of individuals [130]. Our

findings provide a warning that precautions should be taken when considering the

therapeutic use of nicotinic agonists, since patients with severe/critical Covid-19 were

found to release high amounts of ACh, in addition to showing increased levels of M3-

receptor expression. Due to the antiviral and anti-inflammatory effects of AA, it has been

proposed to treat Covid-19 patients [60]. Nevertheless, AA may be not be an adequate

therapeutic target, based on both our findings and previous studies [131], which have shown

that AA can favour hyperinflammation and lethality in Covid-19 infection. In conclusion,

ACh, AA, 5-HETE, and 11-HETE mediate the innate immune response to SARS-CoV-2

and may define the outcome of infection.

Covid-19 severity can be associated with disruption of homeostatic lipidome and

metabolic alterations and this phenomenon may be influenced by comorbidities/risk

factors related to the infection. Our findings demonstrated that (i) high plasma levels of

ACh and lipid mediators positively correlated with Covid-19 severity; and (ii) only

hypertension and/or age were confounding variables for analyzing the association of high

plasma levels of AA, 5-HETE, and ACh with disease severity (Table S7). Similarly, the

correlation between altered plasma profile of lipid mediators and Covid-19 severity is

associated with selective comorbidities – mainly high body mass index (BMI) – but

poorly associated with gender, advanced age, and diabetes. However, the correlation

between altered AA and/or 5-HETE levels and disease severity is associated with male

gender, hypertension, and heart disease, but not BMI[53].

We also examined whether glucocorticoid-therapy interfered with the potential

effect of some confounding variables on the correlation between high ACh levels and

Covid-19 severity in severe/critical patients. Despite the relatively underrepresented

samples from non-glucocorticoid treated patients, no confounding variable significantly

affected the correlation between plasma and BAL ACh levels and Covid-19 severity in

severe/critical patients treated or not with glucocorticoids (Table S8). The altered plasma

and BAL levels of the lipid mediators AA, 5-HETE, and 11-HETE in severe/critical

patients were associated with the disease severity but not with the confounding variables

tested (Table S9). Altogether, the findings here reported suggest that age and/or

hypertension are significant confounding variables for analyzing the association between

increased levels of cholinergic and lipid mediators and Covid-19 severity. Also, the

confounding variables tested probably did not modify the inhibitory action of

glucocorticoids on plasma and BAL ACh levels in severe/critical patients.

To the best of our knowledge, this study is the first to demonstrate that the lung

inflammatory process and poor outcomes of patients with Covid-19 infection are

associated with high levels of lipid mediators and ACh, produced via a partially

glucocorticoid-insensitive pathway. Glucocorticoid therapy was found to lower only the

levels of ACh. Thus, to improve the benefits of glucocorticoid therapy, we suggest that

treatment in hospitalised patients be started early and be preferentially administered to

patients with low or undetectable viral loads and harmful lung inflammation in

combination with AA metabolism inhibitors.

Conclusions

We demonstrate for the first time that the lung inflammatory process and worse

outcomes in Covid-19 are associated with lipid mediators and ACh, which are produced

through a partially glucocorticoid-insensitive pathway. To improve the benefits of

glucocorticoid therapy, we suggest that it should be started early in severe/critical

hospitalized patients and in combination with AA metabolism inhibitors.

References

References

1.   Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019

novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506.

2.   Esser-von Bieren J. Immune-regulation and -functions of eicosanoid lipid

mediators. Biol. Chem. 2017;

3.   Reis M, Rodrigues F, Lautherbach N, et al. Interleukin-1 receptor-induced PGE2

production controls acetylcholine-mediated cardiac dysfunction and mortality

during scorpion envenomation. Nat Commun 2020;11(1).

4.   McGovern AE, Mazzone SB. Neural regulation of inflammation in the airways

and lungs. Auton Neurosci Basic Clin 2014;

5.   Wessler I, Kirkpatrick CJ. Cholinergic signaling controls immune functions and

promotes homeostasis. Int. Immunopharmacol. 2020;

6.   Proskocil BJ, Sekhon HS, Jia Y, et al. Acetylcholine is an autocrine or paracrine

hormone synthesized and secreted by airway bronchial epithelial cells.

Endocrinology 2004;

7.   Chang EH, Chavan SS, Pavlov VA. Cholinergic control of inflammation,

metabolic dysfunction, and cognitive impairment in obesity-associated disorders:

Mechanisms and novel therapeutic opportunities. Front. Neurosci. 2019;

8.   Roy A, Guatimosim S, Prado VF, Gros R, Prado MAM. Cholinergic activity as a

new target in diseases of the heart. Mol Med 2014;

9.   Kistemaker LEM, Gosens R. Acetylcholine beyond bronchoconstriction: roles in

inflammation and remodeling. Trends Pharmacol Sci 2015;36(3):164–71.

10. Profita M, Bonanno A, Siena L, et al. Acetylcholine mediates the release of IL-8

in human bronchial epithelial cells by a NFkB/ERK-dependent mechanism. Eur J

Pharmacol 2008;

11.   Shields MD, Riedler J. Bronchoalveolar lavage and tracheal aspirate for
769   assessing airway inflammation in children. Am J Respir Crit Care Med
770   2000;162(2 II).

771   12.   Schindelin J, Rueden CT, Hiner MC, Eliceiri KW. The ImageJ ecosystem: An
772   open platform for biomedical image analysis. Mol Reprod Dev 2015;82(7–
773   8):518–29.

774   13.   Sorgi CA, Peti APF, Petta T, et al. Data descriptor: Comprehensive high-
775   resolution multiple-reaction monitoring mass spectrometry for targeted
776   eicosanoid assays. Sci Data 2018;

777   14.   Chambers MC, MacLean B, Burke R, et al. A cross-platform toolkit for mass
778   spectrometry and proteomics. Nat. Biotechnol. 2012;

779   15.   Yu T, Park Y, Johnson JM, Jones DP. apLCMS-adaptive processing of high-
780   resolution LC/MS data. Bioinformatics 2009;

781   16.   Li S, Park Y, Duraisingham S, et al. Predicting Network Activity from High
782   Throughput Metabolomics. PLoS Comput Biol 2013;

783   17.   Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of
784   immune perturbations associated with severe COVID-19. Sci Immunol 2020;

785   18.   Desai N, Neyaz A, Szabolcs A, et al. Temporal and spatial heterogeneity of host
786   response to SARS-CoV-2 pulmonary infection. Nat Commun [Internet]
787   2020;11(1):6319. Available from: http://www.nature.com/articles/s41467-020-
788   20139-7

789   19.   Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene
790   expression and hybridization array data repository. Nucleic Acids Res 2002;

791   20.   Russo PST, Ferreira GR, Cardozo LE, et al. CEMiTool: A Bioconductor package
792   for performing comprehensive modular co-expression analyses. BMC

Bioinformatics 2018;

21.   Jassal B, Matthews L, Viteri G, et al. The reactome pathway knowledgebase.

Nucleic Acids Res 2020;

22.   Love MI, Huber W, Anders S. Moderated estimation of fold change and

dispersion for RNA-seq data with DESeq2. Genome Biol 2014;

23.   Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and

Powerful Approach to Multiple Testing. J R Stat Soc Ser B 1995;

24.   Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M.

BioGRID: a general repository for interaction datasets. Nucleic Acids Res 2006;

25.   Csardi G, Nepusz T. The igraph software package for complex network research.

InterJournal Complex Syst 2006;

26.   Maintainer MB, Bojanowski M. Package "intergraph" Type Package Title

Coercion Routines for Network Data Objects. 2016;

27.   Tyner S, Briatte F, Hofmann H. Network visualization with ggplot2. R J

2017;9(1):27–59.

28.   Taylor R. Interpretation of the Correlation Coefficient: A Basic Review. J

Diagnostic Med Sonogr 1990;

29.   Abreu-Filho PG, Tarragô AM, Costa AG, et al. Plasma Eicosanoid Profile in

Plasmodium vivax Malaria: Clinical Analysis and Impacts of Self-Medication.

Front Immunol 2019;

30.   Fukunaga Y, Mine Y, Yoshikawa S, Takeuchi T, Hata F, Yagasaki O. Role of

prostacyclin in acetylcholine release from myenteric plexus of guinea-pig ileum.

Eur J Pharmacol 1993;233(2–3):237–42.

31.   Clark SR, Guy CJ, Scurr MJ, et al. Esterified eicosanoids are acutely generated

by 5-lipoxygenase in primary human neutrophils and in human and murine

818   infection. Blood 2011;

819   32.   Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and

820   moderate coronavirus disease 2019. J Clin Invest 2020;130(5):2620–9.

821   33.   Knight DS, Kotecha T, Razvi Y, et al. COVID-19: Myocardial injury in

822   survivors. Circulation. 2020;

823   34.   Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine

824   signature predicts COVID-19 severity and survival. Nat Med 2020;

825   35.   Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-

826   19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;

827   36.   Polidoro RB, Hagan RS, de Santis Santiago R, Schmidt NW. Overview:

828   Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-

829   CoV-2 Infection Explains Severe Outcomes in COVID-19. Front. Immunol.

830   2020;

831   37.   Shen B, Yi X, Sun Y, et al. Proteomic and Metabolomic Characterization of

832   COVID-19 Patient Sera. Cell 2020;

833   38.   Delafiori J, Claudio Navarro L, Focaccia Siciliano R, et al. Covid-19 automated

834   diagnosis and risk assessment through Metabolomics and Machine-Learning.

835   2020.

836   39.   Bittleman DB, Casale TB. 5-Hydroxyeicosatetraenoic acid (HETE)-induced

837   neutrophil transcellular migration is dependent upon enantiomeric structure. Am

838   J Respir Cell Mol Biol 1995;12(3):260–7.

839   40.   Harder DR. Pressure-induced myogenic activation of cat cerebral arteries is

840   dependent on intact endothelium. Circ Res 1987;

841   41.   Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of

842   COVID-19: Neutrophil extracellular traps. J. Exp. Med. 2020;

843   42.   Kita Y, Takahashi T, Uozumi N, Nallan L, Gelb MH, Shimizu T. Pathway-

844   oriented profiling of lipid mediators in macrophages. Biochem Biophys Res

845   Commun 2005;

846   43.   Gauthier KM, Goldman DH, Aggarwal NT, Chawengsub Y, Falck JR, Campbell

847   WB. Role of arachidonic acid lipoxygenase metabolites in acetylcholine-induced

848   relaxations of mouse arteries. Am J Physiol - Hear Circ Physiol 2011;

849   44.   Rauzi F, Kirkby NS, Edin ML, et al. Aspirin inhibits the production of

850   proangiogenic 15(S)-HETE by platelet cyclooxygenase-1. FASEB J 2016;

851   45.   Berna N, Arnould T, Remacle J, Michiels C. Hypoxia-induced increase in

852   intracellular calcium concentration in endothelial cells: Role of the Na+-glucose

853   cotransporter. J Cell Biochem 2002;

854   46.   López S, Vila L, Breviario F, de Castellarnau C. Interleukin-1 increases 15-

855   hydroxyeicosatetraenoic acid formation in cultured human endothelial cells.

856   Biochim Biophys Acta (BBA)/Lipids Lipid Metab 1993;

857   47.   Metz SA, Murphy RC, Fujimoto W, . Effects on glucose-induced insulin

858   secretion of lipoxygenase-derived metabolites of arachidonic acid. Diabetes

859   1984;33(2):119–24.

860   48.   Hosoi T, Koguchi Y, Sugikawa E, et al. Identification of a novel human

861   eicosanoid receptor coupled to Gi/o. J Biol Chem 2002;

862   49.   Powell WS, Rokach J, ., . The eosinophil chemoattractant 5-oxo-ETE and the

863   OXE receptor. Prog. Lipid Res. 2013;

864   50.   Powell WS, Rokach J. Targeting the OXE receptor as a potential novel therapy

865   for asthma. Biochem Pharmacol 2020;179:113930.

866   51.   Schwarz B, Sharma L, Roberts L, et al. Cutting Edge: Severe SARS-CoV-2

867   Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in

Dysregulation of Eicosanoid Immune Mediators. J Immunol [Internet]

2020;ji2001025. Available from:

http://www.jimmunol.org/content/early/2020/12/04/jimmunol.2001025.abstract

52.   Hanna VS, Hafez EAA. Synopsis of arachidonic acid metabolism: A review. J.

Adv. Res. 2018;

53.   Schwarz B, Sharma L, Roberts L, et al. Severe SARS-CoV-2 infection in humans

is defined by a shift in the serum lipidome resulting in dysregulation of

eicosanoid immune mediators. Res Sq 2020;

54.   Nienhold R, Ciani Y, Koelzer VH, et al. Two distinct immunopathological

profiles in autopsy lungs of COVID-19. Nat Commun [Internet]

2020;11(1):5086. Available from: https://doi.org/10.1038/s41467-020-18854-2

55.   Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical

illness in Covid-19. Nature [Internet] 2020;Available from:

https://doi.org/10.1038/s41586-020-03065-y

56.   Taha AY. Linoleic acid–good or bad for the brain? npj Sci. Food. 2020;

57.   Kohn A, Gitelman J, Inbar M. Unsaturated free fatty acids inactivate animal

enveloped viruses. Arch Virol 1980;

58.   Das UN. Arachidonic acid and other unsaturated fatty acids and some of their

metabolites function as endogenous antimicrobial molecules: A review. J. Adv.

Res. 2018;

59.   Chandrasekharan JA, Sharma-Walia N. Arachidonic acid derived lipid mediators

influence Kaposi's sarcoma-associated herpesvirus infection and pathogenesis.

Front. Microbiol. 2019;

60.   Das UN. Bioactive Lipids in COVID-19-Further Evidence. Arch Med Res 2020;

61.   Nakano T, Ohara O, Teraoka H, Arita H. Glucocorticoids suppress group II

phospholipase A2 production by blocking mRNA synthesis and post-

transcriptional expression. J Biol Chem 1990;

62. Kobza Black A, Greaves M, Hensby C. The effect of systemic prednisolone on

arachidonic acid, and prostaglandin E2 and F2 alpha levels in human cutaneous

inflammation. Br J Clin Pharmacol 1982;

63. Hu X, Cifarelli V, Sun S, Kuda O, Abumrad NA, Su X. Major role of adipocyte

prostaglandin E2 in lipolysis-induced macrophage recruitment. J Lipid Res 2016;

64. Alzoghaibi MA, Walsh SW, Willey A, Yager DR, Fowler AA, Graham MF.

Linoleic acid induces interleukin-8 production by Crohn's human intestinal

smooth muscle cells via arachidonic acid metabolites. Am J Physiol -

Gastrointest Liver Physiol 2004;

65. Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate

endocannabinoid signaling in the nervous system. Chem Rev 2008;108(5):1687–

707.

66. Grant RA, Morales-Nebreda L, Markov NS, et al. Alveolitis in severe SARS-

CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar

macrophages and T cells. bioRxiv 2020;

67. Malcher-Lopes R, Franco A, Tasker JG. Glucocorticoids shift arachidonic acid

metabolism toward endocannabinoid synthesis: A non-genomic anti-

inflammatory switch. Eur. J. Pharmacol. 2008;

68. The RECOVERY Collaborative G. Dexamethasone in Hospitalized Patients with

Covid-19 — Preliminary Report. N Engl J Med 2020;

69. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days

Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory

Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.

JAMA - J Am Med Assoc 2020;

70.   Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The

Current Evidence and Treatment Strategies. Front. Immunol. 2020;

71.   Ye Q, Wang B, Mao J, . The pathogenesis and treatment of the 'Cytokine

Storm'' in COVID-19.' J. Infect. 2020;

72.   Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: Evidence and Hope

during the Pandemic. JAMA - J. Am. Med. Assoc. 2020;

73.   Noushmehr H, D'Amico E, Farilla L, et al. Fatty acid translocase (FAT/CD36) is

localized on insulin-containing granules in human pancreatic β-cells and

mediates fatty acid effects on insulin secretion. Diabetes 2005;

74.   Glatz JFC, Luiken J. From fat to FAT (CD36/SR-B2): Understanding the

regulation of cellular fatty acid uptake. Biochimie. 2017;

75.   Febbraio M, Hajjar DP, Silverstein RL. CD36: A class B scavenger receptor

involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J.

Clin. Invest. 2001;

76.   Glatz JFC, Luiken JJFP, Bonen A. Membrane fatty acid transporters as regulators

of lipid metabolism: Implications for metabolic disease. Physiol. Rev. 2010;

77.   Pepino MY, Kuda O, Samovski D, Abumrad NA. Structure-function of CD36

and importance of fatty acid signal transduction in fat metabolism. Annu. Rev.

Nutr. 2014;

78.   Zoccal KF, Gardinassi LG, Sorgi CA, et al. CD36 shunts eicosanoid metabolism

to repress CD14 Licensed interleukin-1β release and inflammation. Front

Immunol 2018;

79.   Khan NA, Besnard P. Oro-sensory perception of dietary lipids: New insights into

the fat taste transduction. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids. 2009;

80.   Deleon-Pennell KY, Tian Y, Zhang B, et al. CD36 Is a Matrix Metalloproteinase-

944   9 Substrate That Stimulates Neutrophil Apoptosis and Removal during Cardiac

945   Remodeling. Circ Cardiovasc Genet 2016;

946   81.   Novak ML, Thorp EB. Shedding light on impaired efferocytosis and

947   nonresolving inflammation. Circ. Res. 2013;

948   82.   Cundall M, Sun Y, Miranda C, Trudeau JB, Barnes S, Wenzel SE. Neutrophil-

949   derived matrix metalloproteinase-9 is increased in severe asthma and poorly

950   inhibited by glucocorticoids. J Allergy Clin Immunol 2003;

951   83.   Hozumi A, Nishimura Y, Nishiuma T, Kotani Y, Yokoyama M. Induction of

952   MMP-9 in normal human bronchial epithelial cells by TNF-α via NF-κB-

953   mediated pathway. Am J Physiol - Lung Cell Mol Physiol 2001;

954   84.   Ueland T, Holter JC, Holten AR, et al. Distinct and early increase in circulating

955   MMP-9 in COVID-19 patients with respiratory failure: MMP-9 and respiratory

956   failure in COVID-19. J. Infect. 2020;

957   85.   Palau V, Riera M, Soler MJ. ADAM17 inhibition may exert a protective effect

958   on COVID-19. Nephrol Dial Transplant 2020;

959   86.   Laing AG, Lorenc A, del Molino del Barrio I, et al. A dynamic COVID-19

960   immune signature includes associations with poor prognosis. Nat Med 2020;

961   87.   Zhao Y, Qin L, Zhang P, et al. Longitudinal COVID-19 profiling associates IL-

962   1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight

963   2020;

964   88.   Belge K-U, Dayyani F, Horelt A, et al. The Proinflammatory CD14 + CD16 +

965   DR ++ Monocytes Are a Major Source of TNF . J Immunol 2002;

966   89.   Kunkel SL, Standiford T, Kasahara K, Strieter RM. Interleukin-8 (IL-8): The

967   major neutrophil chemotactic factor in the lung. Exp Lung Res 1991;

90. Kunkel TA, Bebenek K, McClary J. Efficient site-directed mutagenesis using

uracil-containing DNA. Methods Enzymol 1991;

91. Zoccal KF, Sorgi CA, Hori JI, et al. Opposing roles of LTB4 and PGE2 in

regulating the inflammasome-dependent scorpion venom-induced mortality. Nat

Commun 2016;

92. De Virgiliis F, Di Giovanni S. Lung innervation in the eye of a cytokine storm:

neuroimmune interactions and COVID-19. Nat Rev Neurol 2020;

93. Carmona-Rivera C, Purmalek MM, Moore E, et al. A role for muscarinic

receptors in neutrophil extracellular trap formation and levamisole-induced

autoimmunity. JCI Insight 2017;

94. do Espírito Santo DA, Lemos ACB, Miranda CH, . In vivo demonstration of

microvascular thrombosis in severe COVID-19. J Thromb Thrombolysis 2020;

95. Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as

emerging drugs for the treatment of obesity. Expert Opin. Emerg. Drugs. 2008;

96. Cavallotti C, Bruzzone P, Mancone M, Leali FMT. Distribution of

acetylcholinesterase and cholineacetyl-transferase activities in coronary vessels

of younger and older adults. Geriatr Gerontol Int 2004;

97. Vijayaraghavan S, Huang B, Blumenthal EM, Berg DK. Arachidonic acid as a

possible negative feedback inhibitor of nicotinic acetylcholine receptors on

neurons. J Neurosci 1995;

98. Mabley J, Gordon S, Pacher P. Nicotine exerts an anti-inflammatory effect in a

murine model of acute lung injury. Inflammation 2011;

99. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced Host Response to

SARS-CoV-2 Drives Development of COVID-19. Cell 2020;

100. Horiguchi K, Horiguchi S, Yamashita N, et al. Expression of SLURP-1, an

993   endogenous α7 nicotinic acetylcholine receptor allosteric ligand, in murine

994   bronchial epithelial cells. J Neurosci Res 2009;

995 101. Schirmer SU, Eckhardt I, Lau H, et al. The cholinergic system in rat testis is of

996   non-neuronal origin. Reproduction 2011;

997 102. Suenaga A, Fujii T, Ogawa H, et al. Up-regulation of lymphocytic cholinergic

998   activity by ONO-4819, a selective prostaglandin EP4 receptor agonist, in MOLT-

999   3 human leukemic T cells. Vascul Pharmacol 2004;

1000 103. Reinheimer T, Münch M, Bittinger F, Racké K, Kirkpatrick CJ, Wessler I.

1001   Glucocorticoids mediate reduction of epithelial acetylcholine content in the

1002   airways of rats and humans. Eur J Pharmacol 1998;

1003 104. Gross I, Ballard PL, Ballard RA, Jones CT, Wilson CM. Corticosteroid

1004   stimulation of phosphatidylcholine synthesis in cultured fetal rabbit lung:

1005   Evidence for de novo protein synthesis mediated by glucocorticoid receptors.

1006   Endocrinology 1983;

1007 105. Nakamura T, Fujiwara R, Ishiguro N, et al. Involvement of choline transporter-

1008   like proteins, CTL1 and CTL2, in glucocorticoid-induced acceleration of

1009   phosphatidylcholine synthesis via increased choline uptake. Biol Pharm Bull

1010   2010;

1011 106. Wilk JB, Shrine NRG, Loehr LR, et al. Genome-wide association studies identify

1012   CHRNA5/3 and HTR4 in the development of airflow obstruction. Am J Respir

1013   Crit Care Med 2012;

1014 107. Lam DCL, Luo SY, Fu KH, et al. Nicotinic acetylcholine receptor expression in

1015   human airway correlates with lung function. Am J Physiol - Lung Cell Mol

1016   Physiol 2016;

1017 108. Oenema TA, Kolahian S, Nanninga JE, et al. Pro-inflammatory mechanisms of

1018   muscarinic receptor stimulation in airway smooth muscle. Respir Res 2010;

1019   109.   Yamada M, Ichinose M. The cholinergic pathways in inflammation: A potential

1020   pharmacotherapeutic target for COPD. Front. Pharmacol. 2018;

1021   110.   Fadason T, Schierding W, Lumley T, O'Sullivan JM. Chromatin interactions and

1022   expression quantitative trait loci reveal genetic drivers of multimorbidities. Nat

1023   Commun 2018;9(1):5198.

1024   111.   Lagoumintzis G, Chasapis CT, Alexandris N, et al. COVID-19 and Cholinergic

1025   Anti-inflammatory Pathway: In silico Identification of an

1026   Interaction between α7 Nicotinic Acetylcholine Receptor and the Cryptic

1027   Epitopes of SARS-CoV and SARS-CoV-2 Spike Glycoproteins. bioRxiv

1028   [Internet] 2020;2020.08.20.259747. Available from:

1029   http://biorxiv.org/content/early/2020/08/21/2020.08.20.259747.abstract

1030   112.   Gahring LC, Myers EJ, Dunn DM, Weiss RB, Rogers SW. Nicotinic alpha 7

1031   receptor expression and modulation of the lung epithelial response to

1032   lipopolysaccharide. PLoS One 2017;

1033   113.   Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor α7 subunit is

1034   an essential regulator of inflammation. Nature 2003;421(6921):384–8.

1035   114.   Pinheiro NM, Santana FPR, Almeida RR, et al. Acute lung injury is reduced by

1036   the a7nAChR agonist PNU-282987 through changes in the macrophage profile.

1037   FASEB J 2017;

1038   115.   Hamano R, Takahashi HK, Iwagaki H, Yoshino T, Nishibori M, Tanaka N.

1039   Stimulation of α7 nicotinic acetylcholine receptor inhibits CD14 and the toll-like

1040   receptor 4 expression in human monocytes. Shock 2006;

1041   116.   Hasday JD, Dubin W, Mongovin S, et al. Bronchoalveolar macrophage CD14

1042   expression: Shift between membrane- associated and soluble pools. Am J Physiol

- Lung Cell Mol Physiol 1997;

117. Gori S, Alcain J, Vanzulli S, et al. Acetylcholine-treated murine dendritic cells

promote inflammatory lung injury. PLoS One 2019;

118. Edwards JM, McCarthy CG, Wenceslau CF. The Obligatory Role of the

Acetylcholine-Induced Endothelium-Dependent Contraction in Hypertension:

Can Arachidonic Acid Resolve this Inflammation? Curr Pharm Des 2020;

119. Radu BM, Osculati AMM, Suku E, et al. All muscarinic acetylcholine receptors

(M1-M5) are expressed in murine brain microvascular endothelium. Sci Rep

2017;

120. Kumar PT, Antony S, Nandhu MS, Sadanandan J, Naijil G, Paulose CS. Vitamin

D3 restores altered cholinergic and insulin receptor expression in the cerebral

cortex and muscarinic M3 receptor expression in pancreatic islets of

streptozotocin induced diabetic rats. J Nutr Biochem 2011;

121. Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and

severity. J. Infect. Public Health. 2020;

122. CHANGEUX jean-pierre, Amoura Z, Rey F, Miyara M. A nicotinic hypothesis

for Covid-19 with preventive and therapeutic implications. Qeios 2020;

123. Oakes JM, Fuchs RM, Gardner JD, Lazartigues E, Yue X. Nicotine and the

renin-angiotensin system. Am. J. Physiol. - Regul. Integr. Comp. Physiol. 2018;

124. Nct. Pyridostigmine in Severe SARS-CoV-2 Infection.

https://clinicaltrials.gov/show/NCT04343963 2020;

125. Ahmed H O. COVID-19: Targeting the cytokine storm via cholinergic anti-

inflammatory (Pyridostigmine). Int J Clin Virol 2020;

126. Gonzalez-Rubio J, Navarro-Lopez C, Lopez-Najera E, et al. Cytokine Release

Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm.

Front Immunol 2020;

127.   ahir AMOURA FT. Efficacy of Nicotine in Preventing COVID-19 Infection in

Caregivers (NICOVID-PREV). Natl Libr Med 2020;2:1–8.

128.   Smith JC, Sausville EL, Girish V, et al. Cigarette Smoke Exposure and

Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor

ACE2 in the Respiratory Tract. Dev Cell 2020;

129.   Leung JM, Leung JM, Yang CX, Sin DD, Sin DD. COVID-19 and nicotine as a

mediator of ACE-2. Eur. Respir. J. 2020;

130.   Zureik M, Baricault B, Vabre C, et al. Nicotine-replacement therapy as a

surrogate of smoking and the risk of hospitalization with Covid-19 and all-cause

mortality a nationwide observational cohort study in France. medrxiv 2020;

131.   Margină D, Ungurianu A, Purdel C, et al. Chronic inflammation in the context of

everyday life: Dietary changes as mitigating factors. Int. J. Environ. Res. Public

Health. 2020;

132.   Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and

inflammatory responses in severe COVID-19 patients. Science (80-) 2020;

133.   Ye G, Pan Z, Pan Y, et al. Clinical characteristics of severe acute respiratory

syndrome coronavirus 2 reactivation. J Infect 2020;

134.   Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected

with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China:

Retrospective case series. BMJ 2020;

135.   Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes

of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy

Region, Italy. JAMA - J Am Med Assoc 2020;

136.   Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set

for COVID-19 clinical research. Lancet Infect. Dis. 2020;

137.   Office WHOEMR. Updated clinical management guideline for COVID-19.

Wkly. Epidemiol. Monit. 2020;

138.   Rauch A, Labreuche J, Lassalle F, et al. Coagulation biomarkers are independent

predictors of increased oxygen requirements in COVID-19. J Thromb Haemost

2020;

139.   Sahu BR, Kampa RK, Padhi A, Panda AK. C-reactive protein: A promising

biomarker for poor prognosis in COVID-19 infection. Clin Chim Acta 2020;

140.   Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics,

Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-

19 in the New York City Area. JAMA [Internet] 2020;323(20):2052–9. Available

from: https://doi.org/10.1001/jama.2020.6775

141.   Thomas T, Stefanoni D, Reisz J, et al. COVID-19 infection results in alterations

of the kynurenine pathway and fatty acid metabolism that correlate with IL-6

levels and renal status. medRxiv Prepr Serv Heal Sci 2020;

142.   Moolamalla STR, Chauhan R, Priyakumar D, Vinod PK. Host metabolic

reprogramming in response to SARS-Cov-2 infection. bioRxiv 2020;

143.   Soliman S, Faris MAIE, Ratemi Z, Halwani R. Switching Host Metabolism as an

Approach to Dampen SARS-CoV-2 Infection. Ann. Nutr. Metab. 2020;

144.   Frankenberger M, Sternsdorf T, Pechumer H, Pforte A, Ziegler-Heitbrock HWL.

Differential cytokine expression in human blood monocyte subpopulations: A

polymerase chain reaction analysis. Blood 1996;

145.   Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex Immune

Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host

Microbe 2020;

146.   Lamontagne F, Brower R, Meade M. Corticosteroid therapy in acute respiratory

distress syndrome. CMAJ. 2013;

147.   Russell CD, Millar JE, Baillie JK. Clinical evidence does not support

corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;

1122

Acknowledgements

The authors thankfully acknowledge Innovation and Technology Park (Supera), the

healthy-participants joining as controls and the positive COVID-19 patients as well as

their families. We grieve for all patients who lost their lives as a result of this pandemic,

including those who provided us with samples to be able to answer scientific questions

and contribute to humanity's eradication of this disease. We also thank Fabiana Rossetto

de Moraes, B.Sc., for the cytometry analysis, Caroline Fontanari, M.Sc., for laboratory

and technical support, the ICU team, and all hospital professionals, especially the

technicians, nurses, physiotherapists, and biomedical personnel, who collaborated on this

work through Hospital Santa Casa de Misericórdia in Ribeirão Preto and Hospital São

Paulo in Ribeirão Preto. We are grateful for the indispensable contribution of the Ribeirão

Preto Municipal Health Department and the employees of the Serviço de Análises

Clínicas (SAC) of the Faculdade de Ciências Farmacêuticas de Ribeirão Preto, USP. We

also thank Professors Victor Hugo Aquino Quintana, Ph.D., Márcia Regina von Zeska

Kress, Ph.D., and Marcia Eliana da Silva Ferreira, Ph.D. for sharing the BSL2 viral

laboratory.

1139

1140

Additional Information

Extended data available in Supplementary Appendixes:

- Supplementary Appendix I - Pathways and list of corresponding genes related to acetylcholine and arachidonic acid observed in Reactome pathways and Covid-19 biomarkers.

- Supplementary Appendix II - Report of CEMITool results for the gene co-expression modular analysis of lung samples from biopsies of Covid-19 and non-Covid-19 patients.

- Supplementary Appendix III - Differential gene expression analysis results between Covid-19-death groups (CV, NCV, CVL and CVH) and Covid-19 samples from patients who underwent glucocorticoid treatment (GC) and not (non-GC).

- Supplementary Appendix IV - Betweenness and degree values of genes from biological network constructed based on the principal co-expression module M1.

Funding

Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP): #2020/05207-6, #2014/07125-6 and #2015/00658-1 for **L.H.F**.; #2020/08534-8 for **M.M.P**.; #2018/22667-0 for **C.O.S.S.;** #2020/05270-0 for **V.D.B**. Additional support was

1164   provided by the National Council for Scientific and Technological Development (CNPq),

1165   the Coordination for the Improvement of Higher Educational Personnel (CAPES-Finance

1166   Code 001)), and Pró-Reitora de Pesquisa da Universidade de São Paulo, grant-USP-

1167   VIDA.

Conflict of Interest Statement

1168

1169   The authors declare that this research was performed without conflicts of interest

1170   or commercial or financial gains.

Legends of main figures

1171

Figure 1. Metabolomic and lipidomic analysis revealed increased levels of

1172

circulating fatty acids, arachidonic acid (AA), 5-HETE and 11-HETE in patients

1173

with Covid-19.

1174

Plasma samples were collected from healthy-participants (n=20) and patients with

asymptomatic-to-mild (n=10), moderate (n=12), severe (n=16), or critical (n=13) disease.

(A) A Manhattan plot for the differential abundance of metabolite features in different

groups of patients with Covid-19 and healthy participants (false discovery rate (FDR) of

595, adjusted P<0.05, above the dashed line) and (B, left panel) metabolic pathway

enrichment of significant metabolite features based on data from untargeted mass

spectrometry. Differential abundance was calculated using the *limma* package for R, and

FDR was controlled using the Benjamini-Hochberg method. Mummichog software v2.3.3

was used for pathway enrichment analysis. (B, right panel) Schematic illustration of the

metabolic pathways involved in the production of hydroxyeicosatetraenoic acids

(HETEs), such as 5-HETE and 11-HETE, from arachidonic (AA) and linoleic acid

metabolism, which discriminate the severity of Covid-19. (C-E) Plasma metabolomics

indicating an increase in free fatty acids in Covid-19. Plasma obtained from healthy

participants (n=18) and patients with asymptomatic-to-mild (n=10), moderate (n=12),

severe (n=14), or critical (n=16) disease (F-H) was subjected to lipidomics analysis using

targeted mass spectrometry, confirming the elevation of AA, 5-HETE and 11-HETE,

according to the severity of Covid-19. Data are expressed as the mean ± SEM. Differences

in (C-H) were considered significant at $P<0.05$ according to Kruskal–Wallis analysis

followed by Dunn's posttest, and specific P-values are shown in each figure.

1194

Figure 2. Systemic markers of inflammation determined Covid-19 severity.

(A-F) Total and differential leukocyte counts in peripheral blood from healthy-

participants (n=17) and from patients with asymptomatic-to-mild (n=10), moderate

(n=12), severe (n=16) or critical (n=13) disease showed that Covid-19 modified the

numbers of distinct leukocyte populations. (G-H) Flow cytometry analysis of

$CD14^+HLA-DR$ circulating monocytes by t-distributed stochastic neighbour embedding

indicated reduced (G) CD14 and (H) CD36 mean fluorescence intensity in asymptomatic-

to-mild (n=16), moderate (n=15), severe (n=35), and critical (n=20) Covid-19 patients

compared to healthy participants (n=12). (I) Soluble CD14 (sCD14), as determined by

ELISA) in healthy participants (n=12), asymptomatic-to-mild (n=12), moderate (n=13),

severe (n=15), and critical (n=15) patients, showed increases only in samples from critical

Covid-19 patients. (J-L) Classical, intermediate, and nonclassical monocytes determined

by flow cytometry analyses of CD14, CD16 and HLA-DR expression in blood cells from

healthy participants (n=12), asymptomatic-to-mild (n=16), moderate (n=15), severe

(n=35), and critical (n=20) Covid-19 patients revealed a decrease in intermediate

monocytes in Covid-19. (M-Q) Cytokines (IL-8, IL-6, IL-1β, TNF and IL-10) quantified

in plasma using a Cytometric Bead Array (CBA) of healthy volunteers (n=35), asymptomatic-to-mild (n=29), moderate (n=35), severe (n=42), and critical (n=21) patients demonstrated a distinct cytokine profile according to disease severity. Data are expressed as the mean ± SEM, and differences between groups were calculated using Kruskal–Wallis with Dunn's multiple comparison post-tests. The specific P-values are displayed in each figure. Differences were considered significant at $P<0.05$.

Figure 3. Altered production of lipid mediators and cellular infiltrates in the lungs drove the local response to SARS-CoV-2 infection.

BAL was collected from intubated patients with severe/critical confirmed Covid-19 diagnosis and from intubated patients without SARS-CoV-2 infection, which are labelled as Covid-19 and non-Covid-19, respectively. Data from untargeted mass spectrometry demonstrated (A) differential abundance of metabolite features comparing Covid-19 and non-Covid-19 participants (Manhattan plot, 595 at FDR adjusted $P<0.05$, above the dashed line) and (B) metabolic pathway enrichment of significant metabolite features. Differential abundance was calculated using the *limma* package for R, and the false discovery rate was controlled using the Benjamini-Hochberg method; Covid-19 (n=26) and non-Covid-19 (n=12). Mummichog software v2.3.3 was used for lipid pathway enrichment analysis. (C) Lipid mediators derived from arachidonic acid (AA) metabolism by lipoxygenase (LOX) or cyclooxygenase (COX) in both Covid-19 (n=19) and non-Covid-19 (n=11) samples, as determined by target mass spectrometry, showed a significant increase in 5-HETE and 11-HETE in Covid-19. (D) Total leukocytes in BAL fluid (left panel) and a representative image of Romanowsky staining in these cells (right panel) used for (E) identification of specific cellular populations in Covid-19 (n=23) and

non-Covid-19 (n=11) patients showed a similar profile of infiltrating cells. (F) Cytokine

concentrations in BAL from intubated Covid-19 patients (n=23) and non-Covid-19

participants (n=11) also revealed a similar profile. (G, H) Classical and intermediate

monocytes determined by flow cytometry analyses of CD14, CD16 and HLA-DR

expression in BAL cells from Covid-19 (n=10) and non-Covid-19 (n=11) patients

demonstrate that both populations are decreased in Covid-19. (I) CD14 and (J) CD36

mean fluorescence intensity (MFI) of $CD14^+HLA-DR$ gated BAL monocytes is

decreased in Covid-19 (n=10) compared to non-Covid-19 (n=11) patients. 5-HPETE: 5-

hydroperoxyeicosatetraenoic acid, LTA_4: leukotriene A_4, LTA_4 hydrolase: leukotriene A_4

hydrolase, LTB_4: leukotriene B_4, 6-trans LTB_4: 6-trans leukotriene B_4, 5-HETE: 5-

hydroxyeicosatetraenoic acid, 11-HETE: 11-hydroxyeicosatetraenoic acid, 12-HETE:

12-hydroxyeicosatetraenoic acid, 15-HETE: 15-hydroxyeicosatetraenoic acid, 5-oxo-

HETE: 5-oxoeicosatetraenoic acid, 12-oxo-ETE: 12-oxoeicosatetraenoic acid, 15-oxo-

HETE: 15-oxoeicosatetraenoic acid, PGH_2: prostaglandin H_2, PGE_2: prostaglandin E_2,

PGD_2: prostaglandin D_2, TXB_2: thromboxane B, TX synthase: thromboxane. Data are

expressed as the mean ± SEM. Differences between groups were calculated using the

Mann–Whitney test, and specific P-values are shown in the figure. Differences were

considered significant at P<0.05.

1253

1254   **Figure 4. Severe and critical phases of Covid-19 correlated with increased systemic**

1255   **and lung acetylcholine and lipid mediators, but only ACh was diminished by**

1256   **glucocorticoids**

1257   Comparison of systemic and local lung responses was analysed using blood and

1258   BAL samples from patients with severe/critical Covid-19 and showed that among (A)

cytokines (plasma n=9; BAL n=9), (B) AA (plasma n=29; BAL n=19), (C) 5-HETE (plasma n=29; BAL n=19), and (D) 11-HETE (plasma n=29; BAL n=19), levels of only AA were higher in blood. (E) The ACh concentration (pmol.mL^{-1}) in heparinized plasma from healthy-participants (n=6) compared to plasma from SARS-CoV-2-infected patients not treated with glucocorticoids (non-GC) classified as having asymptomatic-to-mild (n=5), moderate (n=9), severe (n=7), and critical (n=7) disease showed an increase based on disease severity. (F) ACh in the plasma of patients with Covid-19 at severe/critical stages of the disease and treated (GC, n=18) or not (non-GC, n=14) with glucocorticoids shows decreased release in response to the treatment. (G) Comparison of ACh in BAL from SARS-CoV-2-infected severe/critical patients treated (CG, n=17) or not (non-GC, n=3) with glucocorticoids confirmed inhibition of the neurotransmitter by the treatment. (H) Comparison of neutrophil numbers from blood (n=14) and BAL (n=14) of patients with severe/critical disease demonstrated increased neutrophil infiltration in the lungs. Data are expressed as the mean ± SEM. Differences were considered significant at P<0.05 according to (A) and (E) Kruskal–Wallis tests followed by Dunn's posttest. (B, C, D, F and G) Student's *t*-tests, Mann–Whitney, (H) Wilcoxon matched-pairs signed rank test. Concentrations of ACh in the blood of patients with severe and critical disease and not treated with glucocorticoids were the same, as shown in panels (E) and (F). Blood and BAL were collected during hospitalization, on average 6 to 17 days after admission, and glucocorticoids (methylprednisolone; range 40 to 500 mg/kg/day, or dexamethasone; range 1.5 to 6.0 mg/kg/day) were administered intravenously. Interaction networks between various pairs of mediators quantified in (I) blood (n=151) or (J) BAL (n=32) from our Covid-19 cohort, as constructed using the open access software Cytoscape v3.3 (Cytoscape Consortium, San Diego, CA) and Spearman tests and showing significant correlations depicted by different lines (*r* and P values described in section 7.1). (K-P)

Venn diagram constructed according to the online tool Draw Venn Diagram

(http://bioinformatics.psb.ugent.be/webtools/Venn/) illustrates high-producing patients

in severe and critical stages of disease, with (GC) or without (non-GC) treatment. (K-N)

Plasma from patients producing high levels of AA, 5-HETE, 11-HETE, ACh and sCD14

in GC (n=49) or non-GC (n=17) groups. (O, P) BAL from patients producing high levels

of AA, 5-HETE, 11-HETE, and ACh in GC (n=23) or non-GC (n=4) groups. For analysis,

the global median between controls and patients was considered as the cut-off point. (Q)

Summary data of the values used for construction of the Venn diagrams. The table shows

the absolute number of patients present at each stage of the disease and whether

glucocorticoids were used for each molecule analysed. The percentage of individuals

present in each experimental condition is highlighted in brackets.

1295

Figure 5. Re-analysis of transcriptome data reinforced the correlation between

acetylcholine and arachidonic acid to Covid-19 severity and mortality.

(A) Gene coexpression profile from CVL, CVH, and NCV samples in principal

module M1 (1047 genes, red lines) and mean gene expression (black line) (n=51). Genes

identified as being associated with AA and ACh were only found in module M1; ten are

related to cholinergic receptors and the ACh release cycle and eight to AA metabolism

along with several biomarkers related to Covid-19 severity (Supplementary Appendix II;

Table S4). (B) Heatmap of normalized gene expression related to the ACh and AA

pathways and Covid-19 biomarkers (n=51). Almost all coexpressed genes of the ACh and

AA pathways were upregulated in the CVL versus CVH group, including twelve

cholinergic receptors, six ACh release cycle genes, eighteen AA production and

metabolism pathway genes, and nine eicosanoid receptors (Figure S6A; Supplementary

Appendix III). Approximately 36% of these genes were also upregulated in the CVL versus NCV group but not in the CV versus NCV group (n=51); among them, elongation of very long-chain fatty acid protein 2 (ELOVL2) is involved in linoleic acid metabolism (Figure S6A; Supplementary Appendix III). Cases 3, 9, and 11 were glucocorticoid-treated patients. (C) First-order gene interaction network of the M1 module containing differentially expressed genes related to ACh (brown), AA (green), Covid-19 biomarkers (red), betweenness hubs (blue), and albumin genes (magenta – Covid-19 biomarker and hub). Ten DEGs related to ACh and ten DEGs of AA populated the biological network and are connected to thirteen genes involved in the pathophysiology of Covid-19 and CD36. ACh- and AA-related genes showed relatively low values of centrality metrics and may be under the action of some hub genes, such as oestrogen receptor II (ESR2), insulin-like growth factor II mRNA binding protein (IGF2BP1), albumin (ALB), and others (Supplementary Appendix IV). (D) Plasma and BAL levels of ACh (n=52). ACh levels in BAL fluid exhibited a tendency towards increase compared to plasma samples from deceased or discharged patients. (E) AA (n= 48) and AA concentrations were higher in plasma than in BAL in both patient groups. (F) 5-HETE (n= 48) and (G) 11-HETE (n=47) in several/critical patients according to outcome (discharged or deceased). 5-HETE and 11-HETE levels were only significantly higher in the BAL of deceased patients. (H) Transcription levels of cholinergic muscarinic M3 receptor (CHRM3) and cholinergic receptor nicotinic alpha 7 (CHRNA7) (n=51) and (I) oxoeicosanoid receptor 1 (OXER1) (n=51). A unique gene expression profile in lung samples from Covid-19 patients who had died was characterized by high levels of pro-inflammatory cholinergic receptors (CHRM3, CHRNA3, and CHRNA5) [9,110], low levels of anti-inflammatory cholinergic receptor (CHRNA7) [113], and high expression of oxoeicosanoid receptor 1 (OXER1) [50] which mediates the pro-inflammatory effects of eicosanoids (Figures S6B, S6C). Other

eicosanoid and cholinergic receptors were also differentially expressed in CVL patients

compared to the CVH or NCV group (Figures S6A, S6B, S6C). Finally, transcriptome

analysis of fifteen Covid-19 and five non-Covid-19 samples indicated a correlation

between ACh and AA genes and Covid-19 severity in some CVL patients. Significant

differences in BAL/plasma levels of mediators were set at P< 0.05 according to the

Kruskal-Wallis test followed by Dunn's posttest. *present in module M1. Abbreviations:

Covid-19 low viral load (CVL) - Covid-19 high viral load (CVH) - non-Covid-19 (NCV).

Supplementary Tables

Table S1 – Classification of study participants

Participant's classification	Symptoms, signs, and parameters
Group 1 **Healthy-participants**	• Negative for SARS-Cov-2 nucleicacid • No clinical signs
Group 2 **Asymp-to-mild**	• Positive for SARS-Cov-2 nucleic acid and/or serological test • With or without the following symptoms: diarrhea, cough, fever, headache, loss of taste (ageusia)/smell (anosmia), myalgia, nausea, and vomiting
Group 3 **Moderate**	• Oxygen saturation 94-99 % on room air • Positive for SARS-Cov-2 nucleic acid and/or serological test • Manifestation of mild disease symptoms including dyspnea • Oxygen saturation ≥93% on room air • PaO_2/FiO_2 250-300mmHg • Do not need invasive ventilation: nasal catheter (oxygen 2-4L/min) or oxygen reservoir (oxygen 4-10L/min)
Group 4 **Severe**	• Positive for SARS-Cov-2 nucleic acid and/or serological test • Admission to intensive-care units • Severe respiratory distress • Oxygen saturation <93% on room air • PaO_2/FiO_2 <250mmHg • Need no-invasive ventilation: oxygen reservoir or non-rebreathing face mask (oxygen 10-15L/min).
Group 5 **Critical**	• Positive for SARS-Cov-2 nucleic acid and/or serological test • Admission to intensive-care units • Acute respiratory distress syndrome • Need invasive ventilation • PaO_2/FiO_2 <200mmHg • With or without one or more additional parameters: need hemodialysis, sepsis, septic shock, and multiorgan dysfunction

The participants were classified into five clinical groups (G1–G5): healthy participants (G1) and Covid-19 patients (G2 to G5), based on the severity of disease, clinical parameters, patient's management, and laboratory findings, following the recommendations from WHO [132–137]. These classifications were used to define the scale of the clinical progression of patients. The inclusion criteria were as follows: (i) signed informed consent form; (ii) fit into one of the five clinical groups; (iii) healthy participants must be negative for SARS-CoV-2 nucleic acid; (iv) asymptomatic or symptomatic participants must be positive for SARS-CoV-2 nucleic acid and/or anti-SARS-CoV-2 antibody; (v) age ≥12 years. Participants from groups G1, G2, and G5 were 16

1356   years old or older, while the participants from groups G3 and G4 were 12 years old or older.

1357   Pregnancy was the only exclusion criterion for healthy participants (G1). Abbreviations: FiO_2,

1358   fraction of inspired oxygen; PaO_2, partial pressure of oxygen.

1359

Table S2 – Data of demographic, clinical, and blood findings (n=229)

Baseline Variable	Healthy-participants N= 39	All patients N= 190	COVID-19 care				P value (§)
			Asym-to-mild N= 43	Moderate N= 44	Severe N= 54	Critical N= 49	
Demographic characteristics							
Age median ± SD, (IQR)	36±16.06 (23-80)	53±18.42 (16-96)	39± 10.74 (20-57)	47± 16.90 (16-92)	62± 15.88 (30-96)	66± 16.63 (20-86)	**<0.001**
Gender, No. (%)							
Male	19 (49)	107 (56)	18 (42)	25 (57)	30 (56)	34 (69)	0.400
Female	20 (51)	83 (44)	25 (58)	19 (43)	24 (44)	15 (31)	
Comorbidities or coexisting disorders, No. (%)							
Hypertension	5 (13)	77 (41)	5 (12)	11 (25)	40 (74)	21 (43)	**<0.001**
Dyslipidemia	8 (21)	28 (15)	7 (16)	8 (18)	8 (15)	5 (10)	0.102
Diabetes *mellitus*	1 (3)	51 (27)	3 (7)	11 (25)	25 (46)	12 (24)	**0.002**
Obesity	5 (13)	36 (19)	8 (19)	11 (25)	8 (15)	9 (18)	0.450
Neurological Disease	-	20 (11)	-	3 (7)	8 (15)	9 (18)	-
Respiratory Disorders	1 (3)	34 (18)	12 (28)	10 (23)	3 (6)	9 (18)	**<0.001**
Symptoms, No. (%)							
Dyspnea	-	103 (54)	3 (7)	35 (80)	36 (67)	29 (59)	-
Fever	-	57 (30)	1 (2)	10 (23)	26 (48)	20 (41)	-
Myalgia	-	40 (21)	-	8 (18)	19 (35)	13 (27)	-
Diarrhea	-	48 (25)	13 (30)	13 (30)	13 (24)	9 (18)	-
Cough	-	127 (67)	25 (58)	34 (77)	41 (76)	27 (55)	-
Anosmia	-	59 (31)	27 (63)	19 (43)	7 (13)	6 (12)	-
Dysgeusia	-	57 (30)	25 (58)	19 (43)	8 (15)	5 (10)	-
Headache	-	13 (7)	-	4 (9)	5 (9)	4 (8)	-
Laboratory findings, median ± SD, (IQR)							
Erythrocytes (10^9 L^{-1})	4.7±0.48 (4.0-5,8)	4.4±0.88 (1.1-5.9)	4.8±0.46 (3.9-5.9)	4.5±0.71 (2.9-5.9)	4.4±0.99 (1.1-5.9)	3.7±0.67 (2-5.8)	**0.0034**
Hemoglobin (g dL^{-1})	15.0±1.55 (11.3-17.5)	13.1±2.68 (6.5-18.2)	14.5±1.28 (12.0-18.2)	13.9±2.26 (8.4-18.2)	12.9±2.64 (6.8-17.6)	10.7±2.65 (6.5-18.2)	**0.001**
Leukocytes (10^9 L^{-1})	7.5±1.71 (4.1-11.2)	8.8±5.24 (1.6-33.0)	7.3±2.28 (3.2-13.6)	7.7±2.82 (2.6-14.9)	8.6±5.23 (1.6-33.0)	13.2±6.00 (5.2-29.0)	**0.042**
Neutrophils (10^9 L^{-1})	4.2±0.99 (2.4-6.0)	6.3±4.90 (1.6-26.1)	4.1±1.76 (1.6-9.9)	4.9±2.72 (1.8-13.4)	6.8±4.31 (0.24-25.1)	11.4±5.36 (3.7-26.1)	**<0.001**
Lymphocytes (10^9 L^{-1})	2.5±0.85 (1.2-5.1)	1.4±0.93 (0.1-4.3)	2.3±0.67 (1.2-4.3)	2.0±0.90 (0.3-4.2)	1.1±0.82 (0.1-4.1)	0.9±0.54 (0.2-2.6)	**<0.001**
RNL	1.8±0.56 (1-3.1)	5.1± 14.93 (0.6-115.4)	1.7±0.62 (0.7-3.6)	3±5.61 (0.6-29.7)	6.6±18.23 (1.3-115.4)	11.9±18.30 (3.4-92)	**<0.001**
Monocytes (10^9 L^{-1})	0.5±0.17 (0.3-0.9)	0.5±0.38 (0.0-2.6)	0.5±0.17 (0.3-0.9)	0.4±0.23 (0.1-1.2)	0.5±0.45 (0.0-2.0)	0.5±0.52 (0.0-2.6)	0.207
Platelets (10^9 L^{-1})	216±37.34 (129-297)	236± 93.69 (50-635)	227±67.10 (135-474)	234± 88.93 (117-515)	251± 108.5 (85-635)	234±98.67 (50-620)	**0.039**
Glycemia (mg dL^{-1})	90±10.14 (76-113)	113.5±70.37 (28-479)	88±72.88 (65-479)	99.5±39.38 (65-262)	142±78.65 (28-409)	147.5±59.90 (76-301)	**<0.001**

TTPa (seconds)	26.0±2,49 (21.8-31.7)	26.7±5.65 (0.0-64.1)	26.2±3.28 (20.4-38.6)	26.6±4.80 (18.2-41.4)	27.8±3.66 (20.5-35.2)	26.7±9.38 (0.0-64.1)	0.167
TP (seconds)	13.6±1.68 (12.6-21.7)	13.1±2.1 (0.0-18.1)	13.3±1.29 (12.1-17.5)	13.2±1.17 (11.0-15.2)	12.6±2.65 (0.0-15.7)	13.3±2.81 (0.0-18.1)	**0.041**
INR	1.12±0.17 (1.0-1.97)	1.1±0.16 (0.0-1.6)	1.1±0.13 (1.0-1.5)	1.1±0.10 (0.9-1.4)	1.1±0.11 (1.0-1.4)	1.2±0.25 (0.0-1.6)	0.106
Hospital support, No. (%)							
Infirmary	-	73 (38)	-	20 (45)	50 (93)	3 (6)	-
Intensive care unit (ICU)	-	53 (28)	-	3 (7)	4 (7)	46 (94)	-
Hospitalization data, No.							
Hospitalization days, median (IQR)	-	10 (1-34)	-	2 (1-23)	9 (1-22)	14 (4-34)	
Infection data, median ± SD, (IQR)							
Infection days	-	5±2.74 (1-16)	-	5±2.54 (1-10)	5±2.97 (2-16)	5±2.58 (1-10)	
Respiratory support received (%)							
Nasal-cannula oxygen	-	58 (31)	-	18 (41)	38 (70)	2 (4)	-
Non-rebreathing mask / Non-invasive ventilation	-	21 (11)	-	-	15 (28)	6 (12)	-
Invasive mechanical ventilation	-	41 (22)	-	-	1 (2)	40 (82)	-
Oxygen saturation median ± SD (IQR)	98.0±2,16 (90-99)	94.0±11,00 (86-100)	98.0±1.79 (93-99)	97.0±4.40 (80-100)	90.5±15.3 (86-99)	91.5±9.84 (66-99)	**<0.001**
Denouement, No (%)							
Discharge	-	61 (32.1)	-	20 (45.5)	32 (59.3)	9 (18.4)	-
Death	-	65 (34.2)	-	3 (6.8)	22 (40.7)	40 (81.6)	-
Medications No. (%)							
Dexamethasone	-	100 (53)	-	14 (32)	45 (83)	41 (84)	-
Azithromycin	-	98 (52)	1 (2)	18 (41)	52 (96)	28 (57)	-
Ceftriaxone	-	110 (58)	13 (30)	17 (39)	50 (93)	30 (61)	-
Oseltamivir	-	64 (34)	-	4 (9)	37 (69)	23 (47)	-
Cloroquine/Hydroxycloroquine	-	33 (17)	-	3 (7)	13 (24)	17 (35)	-
Anticoagulant	1 (3)	4 (2)	1 (2)	-	-	3 (6)	-
Ivermectin	-	2 (1)	-	1 (2)	1(2)	-	-

1362

Abbreviations: N, number of participants; SD, standard deviation; IQR, interquartile; RNL, ratio between neutrophils and lymphocytes; N

(%); TTPa, activated partial thromboplastin time; TP, prothrombin time; INR, international normalised ratio. §Comparison of the control

group (healthy participants) with all patients. The values were compared using the χ^2 test and one-way analysis of variance (ANOVA),

Mann-Whitney test, and nonparametric t-tests for continuous variables. $p<0.05$ was considered statistically significant.

Table S3 - Demographic, clinical characteristics and blood findings data from

severe/critical participants of which bronchoalveolar lavage (BAL) were collected

(n=45)

Baseline Variable BAL	non-Covid-19 Patients N= 13	Covid-19 N= 32	p Value (§)
Demographic characteristics			
Age median ± SD, (IQR)	61±21.2 (20-82)	66.5±17 (25-86)	0,4237
Gender, No. (%)			
Male	4 (30,8)	21 (65.6)	-
Female	9 (69,2)	11 (4.4)	-
Comorbidities or coexisting disorders, No. (%)			
Hypertension	4 (30.77)	16 (51.61)	0,2052
Dyslipidemia	-	2 (6.45)	-
Diabetes *mellitus*	2 (15.38)	8 (25.81)	0,4517
Obesity	1 (7.69)	3 (9.68)	0,8345
Neurological	2 (15.38)	4 (12.90)	0,8268
Respiratory disorders	7 (53.85)	3 (9.68)	**0,0014**
Presenting symptoms, No. (%)			
Dyspnea	4 (30.8)	18 (58.1)	
Fever	-	14 (45.2)	-
Myalgia	-	10 (32.3)	-
Diarrehea	-	7 (22.6)	-
Cough	-	18 (58.1)	-
Hyperactive Delirium	-	-	-
Dysgeusia	-	3 (9.7)	-
Anosmia	-	4 (12.9)	-
Astemia	-	3 (9.7)	-
Laboratory findings, median ± SD, (IQR)			
Erythrocytes (10^{12} L^{-1})	2.7±0.94 (1.6-5.2)	3.5±0.70 (2-5.3)	0,0175
Hemoglobin (g dL^{-1})	8.7±2.93 (4.6-15.2)	10.3±2.19 (6.5-16.2)	0,0319
Leukocytes (10^9 L^{-1})	11.5±15.44 (7.8-62.4)	11.8±6.70 (4.6-29.0)	0,7848
Neutrophils (10^9 L^{-1})	8.6±11.18 (4.5-45.5)	9.6±5.95 (3.3-26.1)	0,9842
Lymphocytes (10^9 L^{-1})	1.2±1.08 (0.3-4.4)	0.9±0.54 (0.4-2.2)	0,2127
RNL	7±21.15 (2.6-73)	11.0±10.05 (3.36-43.5)	0,2925
Monocytes (10^9 L^{-1})	0.6±0.51 (0.3-1.8)	0.6±0.55 (0-2.6)	0,5627
Platelets (10^9 L^{-1})	254±165.8 (71-553)	252±86.8 (50-414)	0,4519
Glycemia (mg dL^{-1})	151.5±85.91 (9.8-376)	148±58.23 (76-300)	0,5848
TP	13.2±1.97 (11.5-17.1)	13.1±3.34 (0-18.1)	0,8464
TTPa	25.5±6.30 (22.6-46)	25.2±10.96 (0-64.1)	0,6380
INR	1.1±0.18 (0.1-1.5)	1.2±0.30 (0-1.6)	0,9632
Respiratory support received (%)			
Oxygen Saturation median ± SD (IQR)	94±6.41 (78-100)	91±10.36 (66-99)	0,0500
Hospitalization data, No.			
Hospitalization days, median (IQR)	22±11.41 (6-43)	14±15.36 (5-34)	0,0888
Infeccions data, median ± SD, (IQR)			
Infection days	4±3.27 (2-10)	6±2.46 (0-11)	0,3166
Denouement, No (%)			
Discharge	9 (69.2)	4 (12.9)	-
Death	4 (30.8)	28 (87.5)	-
Medications No. (%)			
Dexamethasone	2 (15.38)	26 (83.87)	**< 0,0001**
Azithromycin	1 (7.69)	2 (6.45)	0,8816
Ceftriaxone	10 (76.92)	25 (78.13)	0,9300
Oseltamivir	1 (7.69)	16 (51.61)	**0,0063**
Cloroquine/Hydroxycloroquine	1 (7.69)	10 (32.26)	0,0860
Anticoagulant	-	-	-
Ivermectin	-	-	-

1370

Abbreviations: N, number or values; SD, standard deviation; IQR, minimum and maximum values; RNL, ratio between neutrophils and lymphocytes; N (%); TTPa, activated partial thromboplastin time; TP, prothrombin time; INR, international normalised ratio. §Comparison of the Covid-19 negative patients group with Covid-19 positive patients. The values were compared using the χ^2 test and one-way analysis of variance (ANOVA), Mann-Whitney test, and nonparametric t-tests for continuous variables. $p < 0.05$ was considered statistically significant.

1378 **Table S4 – List of genes related to acetylcholine and arachidonic acid**

1379 **pathways and Covid-19 biomarkers founded in co-expression module M1**

Gene (symbol)	Gene (name)	Pathway or Biomarker
CHRM2	cholinergic receptor muscarinic 2	
CHRM3	cholinergic receptor muscarinic 3	
CHRM5	cholinergic receptor muscarinic 5	
CHRNA2	cholinergic receptor nicotinic alpha 2 subunit	
CHRNA3	cholinergic receptor nicotinic alpha 3 subunit	
CHRNA4	cholinergic receptor nicotinic alpha 4 subunit	Acetylcholine
CHRNA5	cholinergic receptor nicotinic alpha 5 subunit	
CHRNB2	cholinergic receptor nicotinic beta 2 subunit	
PPFIA4	PTPRF interacting protein alpha 4	
RIMS1	regulating synaptic membrane exocytosis 1	
ALOX15	arachidonate 15-lipoxygenase	
CYP4F3	cytochrome P450 family 4 subfamily F member 3	
CYP4A11	cytochrome P450 family 4 subfamily A member 11	
CYP8B1	cytochrome P450 family 4 subfamily B member 1	
CYP4F8	cytochrome P450 family 4 subfamily F member 8	Arachidonic acid
CYP2C8	cytochrome P450 family 2 subfamily C member 8	
CYP1A1	cytochrome P450 family 1 subfamily A member 1	
DPEP2	dipeptidase 2	
ALB	Albumin	
CRP	C-reactive protein	
CXCL8 (IL8)	C-X-C motif chemokine ligand 8	
FGA	fibrinogen alpha chain	Biomarker (COVID-19)
FGB	fibrinogen beta chain	
IL1β	interleukin 1 beta	

1380

1381 Co-expression analysis generated five different co-expression gene modules (M1 to

1382 M5) and only in M1 we identified genes that encoding proteins associated to

1383 cholinergic receptors (muscarinic and nicotinic), ACh release cycle, and AA

1384 metabolism. In addition, the M1 module also contains some biomarkers related to

Covid-19 severity (albumin, C-reactive protein, IL-8, fibrinogen, and IL1β)
[21,34,138,139].

Table S5 - Treatment of severe and critical Covid-19 patients with glucocorticoids does not alter the levels of plasmatic cytokines and circulating neutrophils and lymphocytes

	Severe non-GC N=3	Severe GC N=39	P value (#)	Critical non-GC N=4	Critical GC N=17	P value (§)
Parameters, median ± SEM, (IQR)						
IL-8	31.7±12.6 (13.6-56.0)	26.3±4.97 (2.8-186.4)	0.454	26.86±6.5 (10.2-41.8)	113.2±48.8 (13.1-661.9)	0.144
IL-6	42.7±20.1 (4.80-73.2)	54.9±14.19 (3.3-414.1)	0.782	46.4±13.2 (24.7-81.7)	317.7 ±160.3 (11.3-2510)	0.410
IL-1	2.5±2.5 (0.0-7.6)	0.1±0.05 (0.0-1.7)	0.104	0.9±0.9 (0.0-3.6)	0.5±0.3 (0.0-3.8)	0.874
TNF	0.0±0.0 (0.0-0.0)	0.01±0.1 (0.0-0.3)	>0.999	0.8±0.8 (0.0-3.1)	0.04±0.04 (0.0-0.7)	0.191
IL-10	1.0±0.5 (0.4-2.1)	2.7±0.4 (0.3-9.1)	0.165	2.3±1.1 (0.8-4.3)	7.5 ±2.6 (0.1-45.1)	0.229
Neutrophils	56.5±20.8 (15.0-77.5)	80.5±1.7 (38.6-97.0)	0.097	79.9±3.8 (73.1-89.0)	85.6±1.5 (70.1-93.0)	0.197
Lymphocytes	9.7±1.6 (8.0-13.0)	12.0±0.9 (2.0-27.8)	0.490	10.9±2.2 (5.0-14.7)	7.9±1.0 (4.0-20.5)	0.156
RNL	5.7±2.2 (1.9-9.4)	10.2±1.6 (2.2-47.5)	0.403	9.0±2.7 (5.1-16.6)	13.3±1.5 (3.4-23.3)	0.140

Abbreviations: N, number of participants; SEM, standard error of the mean; IQR, interquartile; RNL, ratio between neutrophils and lymphocytes. §Comparison of the severe non-GC group with the severe GC group, and the critical non-GC group with the critical GC group. The values were compared using the χ^2 test, one-way analysis of variance (ANOVA), Mann-Whitney test, and nonparametric t-tests for continuous variables. $p<0.05$ was considered statistically significant.

As shown in the table, glucocorticoid therapy in severe Covid-19 patients did not show a statistically significant influence on the plasma levels of the cytokines evaluated in our study. The use of glucocorticoids and their impact on the production of inflammatory molecules is closely associated with several factors, such as the dose, duration, and time of initiation of therapy, since,

1400 in the critical stages of Covid-19, no beneficial effects of glucocorticoids have been observed in

1401 the inflammation control and patient outcome [70,71].

1402 **Table S6 - Impact of glucocorticoid therapy in the outcome of hospitalized Covid-**

1403 **19 patients**

No, (%)	Moderate N=23		Severe N=54		Critical N=49	
	Discharge N=20	Death N=3	Discharge N=32	Death N=22	Discharge N=9	Death N=40
non-GC	7 (35)	0 (0)	4 (12.5)	3 (13.6)	4 (44.4)	9 (22.5)
GC	13 (62)	3 (100)	28 (87.5)	19 (86.4)	5 (55.6)	31 (77.5)

1404

Abbreviations: N, number of participants (%).

Hospitalised Covid-19 patients from the moderate, severe, and critical groups were

administered glucocorticoid (GC) therapy or not (non-GC) (methylprednisolone; range 40 to 500

mg/kg/day, or dexamethasone; range 1.5 to 6.0 mg/kg/day, by intravenous route). Most

hospitalised patients were treated with glucocorticoids (moderate [69.6%], severe [87.0%], and

critical [73.5%]). All moderate non-GC-patients were discharged, while GC patients had a

mortality rate of 18.8%. In addition, the mortality rates for severe-GC (40.4%) and critical-GC

(86.1%) patients were higher than those for moderate-CG patients. The discharge rates of non-

GC patients vary according to the clinical categorization (100.0%, 57.1%, and 30.8% for

moderate, severe, and critical, respectively). Hospitalised Covid-19 patients from our cohort

showed fewer benefits of glucocorticoid therapy than those reported in the RECOVERY trial [68],

but similar benefits to those described in the CoDEX trial conducted in Brazil [69]. This reduction

of glucocorticoid benefits could be associated with several factors, including a low mean

$PaO_2:FiO_2$ ratio and an overload of the health systems of countries with limited resources, such

as Brazil [69], as well as glucocorticoid dose, initiation, and duration of therapy [70,71].

1420

Table S7 – Analysis of the potential interference of Covid-19-confounding variables on the correlation between high plasma levels of cholinergic and lipid mediators and Covid-19 severity.

Confounding variables	Healthy participants	Asym-to-mild	Moderate	Severe	Critical	P value (§)
Lipid mediators (AA, 5-HETE, and 11-HETE)						
No	17	10	11	**16**	11	
Age, mean (IQR)	**33 (27-44)**	**33 (26-43)**	**39 (30-48)**	**57 (48-78)**	**71 (57-78)**	**<0.001**
Gender, No (%) Male						0.795
Female	7 (41.2)	5 (50.0)	6 (54.5)	7 (43.8)	7 (63.6)	
Diabetes, No (%)	10 (58.8)	5 (50.0)	5 (45.5)	9 (56.2)	4 (36.4)	
Hypertension, No (%)	1 (5.9)	1 (10.0)	3 (27.3)	6 (37.5)	2 (18.2)	0.183
Obesity, No (%)	**2 (11.8)**	**0 (0.0)**	**0 (0.0)**	**12 (75.0)**	**6 (54.5)**	**<0.001**
	4 (23.5)	2 (20.0)	3 (27.3)	2 (12.5)	1 (9.1)	0.7788
ACh						
No	6	5	4	6	8	
Age, mean (IQR)	**30 (24-56)**	**42 (38-46)**	**48 (39-57)**	**75 (63-79)**	**65 (52-74)**	**0.026**
Gender, No (%) Male						0.290
Female	4 (66.7)	3 (60.0)	2 (50.0)	1 (16.7)	6 (75.0)	
Diabetes, No. (%)	2 (33.3)	2 (40.0)	2 (50.0)	5 (83.3)	2 (25.0)	
Hypertension, No. (%)	0 (0.0)	1 (20.0)	1 (25.0)	3 (50.0)	1 (12.5)	0.282
Obesity, No. (%)	2 (33.3)	2 (40.0)	1 (25.0)	5 (83.3)	3 (37.5)	0.360
	1 (16.7)	1 (20.0)	0 (0.0)	0 (0.0)	2 (25.0)	0.767

We analysed some confounding variables associated with Covid-19, such as comorbidities (Diabetes mellitus, hypertension, and obesity) and risk factors (advance age and gender) [51,140], using data from participants whose plasma levels of lipid mediators (AA, 5-HETE, and 11-HETE) and ACh were measured. Lipid mediators data came from Covid-19 patients and heathy participants presented in Figure 1 (Panels: F, G, and H), while ACh data came from glucocorticoid-non-treated Covid-19 patients presented in Figure 4E. Age and hypertension or only age are potential confounding variables on the correlation between high plasma levels of lipid mediators or ACh and Covid-19 severity, because (i) age had significant Spearman's correlation with AA (r=0.36; P=0.0042), 5-HETE (r=0.36; P=0.0042), and ACh (r=0.37; P =0.0485); and (ii) hypertensive patients had significantly increased plasma levels of AA (*p*=0.0062 - Mann-Whitney test). §Kruskal-Wallis or Fisher's tests were used to compare the differences between all clinical categories. Data are expressed as median (IQR - interquartile range) or number (% - percentages), and P < 0.05 was considered statistically significant.

Table S8 - **Analysis of the potential interference of Covid-19-confounding variables on the correlation between high ACh levels in severe/critical patients, treated or not with glucocorticoids, and Covid-19 severity.**

Confounding variables	Severe (Plasm)			Critical (Plasm)			Critical (BAL)		
	non-GC	GC	P value (§)	non-GC	GC	P value (§)	non-GC	GC	P value (§)
No	6	10		8	8		3	17	
Age, median (IQR)	75 (63-79)	68 (55-76)	0.415	65 (52-74)	76 (60-79)	0.316	74 (72-80)	62 (53-76)	0.243
Gender, No (%)			0.118			1.000			0.920
Male	1 (16.7)	7 (70.0)		6 (75.0)	6 (75.0)		2 (66.7)	11 (64.7)	
Female Diabetes,	5 (83.3)	3 (30.0)		2 (25.0)	2 (25.0)		1 (33.3)	6 (35.3)	
No (%)	4 (40.0)	6 (60.0)	1.000	1 (12.5)	3 (37.5)	0.569	1 (33.3)	3 (17.6)	0.450
Hypertension, No (%)	2 (20.0)	8 (80.0)	1.000	3 (37.5)	5 (62.5)	0.619	3 (100.0)	6 (35.3)	0.073
Obesity, No (%)	0 (0.0)	1 (10.0)	1.000	2 (25.0)	2 (25.0)	1.000	0 (0.0)	3 (17.6)	1.000

1440

Here we used the same confounding variables associated with Covid-19 described on Table S7. This analysis was based on plasma and BAL cholinergic mediator (ACh) data from severe/critical Covid-19 patients, treated (GC) or not (non-GC) with glucocorticoids, and reported in Figure 4 (Panels: F and G). None of the confounding variables tested had significant potential to interfere with the glucocorticoid-therapy ability to reduce the high plasma and BAL ACh levels in severe/critical patients. §Mann-Whitney or Fisher's tests were used to compare the differences between severe and critical clinical categories. Data are expressed as median (IQR - interquartile range) or number (% - percentages), and $P < 0.05$ was considered statistically significant.

Table S9 - Impact of Covid-19 confounding variables on the comparative analysis between high levels of lipid mediators in plasma and BAL samples from severe and critical patients.

Confounding variables	Severe/Critical (Plasm)	Severe/Critical (BAL)	P value (§)
No	25	18	
Age, median (IQR)	60 (53-77)	64 (52-83)	0.6395
Gender, No. (%) Male			0.1394
Female	14 (56.0)	14 (77.8)	
Diabetes, No. (%)	11 (44.0)	4 (22.2)	
Hypertension, No. (%)	7 (28.0)	5 (27.8)	0.9872
Obesity, No. (%)	16 (64.0)	9 (50.0)	0.3586
	3 (12.0)	4 (22.2)	0.4274

We used the same confounding variables associated with Covid-19 reported on Table S7. This analysis was based on plasma and BAL levels of lipid mediators (AA, 5-HETE, and 11-HETE) from severe/critical Covid-19 patients reported in Figure 4 (Panels: B, C, and D). None of the confounding variables tested had significant potential to interfere with the comparison between altered plasm and BAL levels of lipid mediators in severe/critical patients. §Mann-Whitney, chi-square, or Fisher's tests were used to compare the differences between severe and critical patients. Data are expressed as median (IQR - interquartile range) or number (% - percentages), and P < 0.05 was considered statistically significant.

1462 **Supplementary Figures**

1463 **Figure S1 – Metabolic signatures of plasma and BAL samples from patients**

1464 **infected or not with SARS-CoV-2.**

1465

Hierarchical clustering based on different characteristics of abundant metabolites

(ANOVA-FDR <0.1) between controls and patients positive for SARS-CoV-2 at different stages

of the disease in plasma (A) and non-Covid-19 versus Covid-19 BAL patients (B). In (A), the

clinical classification of Covid-19 was: healthy participants (n=20), asymptomatic-to-mild

(n=10), moderate (n=12), severe (n=16), and critical (n=13) groups. In (B), the same analysis was

performed with data from BAL samples of non-Covid-19 (n=12) and Covid-19 (n=26) patients.

The detection levels of metabolites were defined using Z-score normalisation.

The analysis of hierarchical clustering (A) shows highly different metabolomic profiles

in the plasma for each group of individuals according to disease severity. BAL analysis (B) of

samples from Covid-19 patients demonstrated an increase in the abundance of metabolites

compared to non-Covid-19 individuals. The results indicated that SARS-CoV-2 infection induces

changes in the metabolic profile of humans. Our data are in agreement with previous results

showing virus-induced metabolic reprogramming in the host. The increased abundance of

metabolites and their pathways, such as free fatty acids and amino acids, was correlated to the

increase in viral proliferation, since these biomolecules can act as building blocks and fuel for

this process [141–143].

Figure S2 - Gating strategy used for flow cytometry analysis of monocyte subsets

and CD14/CD36 expression

1484

1485

In (A), dot plots show a representative gating strategy for the analysis of FSC-H/FSC-A,

SSC-A/FVS-620 (viable cells), and SSC-A/FSC-A, followed by CD14+HLA-DR+ monocytes and

the classical (CD14^{high}CD16^{-}), intermediate (CD14^{+}CD16^{+}) or non-classical CD14^{low}CD16^{+}

subsets, with subsequent CD36 mean fluorescence intensity (MFI) in whole blood (upper panel)

and bronchoalveolar lavage fluid (BAL, bottom panel). In (B), a violin plot shows the frequency

of non-classical monocytes from BAL of non-Covid-19 and Covid-19 patients. In (C), CD36 MFI

in classical, intermediate, and non-classical monocytes from BAL of non-Covid-19 and Covid-

19 samples. Differences between groups were calculated using the Mann-Whitney test.

The membrane markers and gating strategies used to define the different monocyte

subpopulations in the blood and BAL samples were adapted from a previous publication (ref). In

BAL, there was a tendency to reduce non-classical monocytes in Covid-19 patients compared to

non-Covid-19 patients (Figure 2SB), as well as a decrease in CD36 expression in classical and

intermediate monocytes (Figure 2SC), although the difference was not statistically significant.

Although not significantly, this reduction may have a biological importance. These data are

similar to the profile observed in the blood monocytes of Covid-19 patients (Figure 3J).

Figure S3 - Determination of monocyte subsets in the blood and BAL samples from non-Covid-19 and Covid-19 patients

Peripheral blood from healthy participants (n=12), and asymptomatic-to-mild (n=15), moderate (n=15), severe (n=35), or critical (n=20) patients, and BAL from Covid-19 (n=10) and non-Covid-19 (n=11) participants were collected and used for the characterisation of monocyte subpopulations by flow cytometry and t-distributed stochastic neighbour embedding (t-SNE) analysis. (A) Frequency of CD14$^+$HLA-DR$^+$ cells. (B) t-SNE evaluation of classical (CD14^{high}CD16$^-$), intermediate (CD14$^+$CD16$^+$),

and non-classical $CD14^{low}CD16^{+}$ blood monocytes in Covid-19 patients, categorised

according to disease severity. (C) Colour mapping t-SNE and violin plot showing the

mean fluorescence intensity (MFI) of HLA-DR expression in the circulating monocytes

of Covid-19 subjects. In (D) and (E), samples of BAL from non-Covid-19 and Covid-19

patients were evaluated to determine the frequency of $CD14^{+}HLA-DR^{+}$ cells and

classical, intermediate, or non-classical monocyte subsets, respectively. Differences

among groups were calculated using the Kruskal-Wallis test with Dunn's multiple

comparison post-test, and the corresponding values are indicated in the figures.

In comparison to healthy participants (Figure S3A, S3B, and 3SC), a significant

reduction was observed in the intermediate monocyte population, as well as in the

expression of HLA-DR molecules in the blood of Covid-19 patients, depending on

disease severity. The diminishment of HLA-DR in monocytes correlated with TNF values

obtained in the blood of patients positive for SARS-CoV-2 (Figure 2P; principal article),

since monocytes with a pro-inflammatory profile are the main producers of this cytokine

[144]. Similarly, reduced intermediate monocytes were found in the BAL of patients positive

for Covid-19 (Figure S3E). Interestingly, these patients also had a significant increase in

the production of IL-8, IL-10, and IL-6 cytokines in the blood and BAL, as shown before

(Figure 2M, 2N, and 2Q and Figure 4A; principal article). The high production of

cytokines, especially IL-6, in patients with Covid-19, has been correlated with a decrease

in the expression of HLA-DR in monocytes, while the therapeutic inhibition of IL-6 re-

established the expression of this molecule in those individuals[145]

Figure S4 - Biomarker networks in non-Covid-19 and healthy participants

1535

A network of interactions between lipid mediators, ACh, sCD14, and cytokines in (A)

healthy participants (n=39) and (B) BAL non-Covid-19 participants (n=13). Network layouts of

personalised biomarkers were set up to identify the relevant association in healthy and non-Covid-

19 participants. Each connecting line denotes a significant correlation between a pair of markers.

Continuous lines represent positive correlations, while dashed lines represent negative

correlations ($p<0.05$). The degree of significance is represented by the thickness of the line.

Correlations were determined using Spearman's test; the values of r and p were used to classify

the connections as weak ($r \leq 0.35$, $p<0.05$), moderate ($r = 0.36$–0.67, $p<0.01$), or strong ($r \geq 0.68$,

$p< 0.001$). The absence of a line indicates the non-existence of the relationship. To evaluate the

relationship between levels of lipid mediators, ACh, sCD14, and cytokines in non-Covid-19, a

series of correlation analyses were performed.

When comparing the interactions analysed between the molecules of the healthy and non-

Covid-19 groups, we observed that (A) In the blood of healthy individuals, the interactions were

found to occur mainly between cytokines (IL-1β, TNF, IL-8, IL-6, and IL-10) and the lipid

mediator 5-HETE. (B) In thee BAL samples from hospitalised non-Covid-19 patients, lipid

mediators were found to mediate these interactions and influence the clinical outcomes of this

group of patients.

 Figure S5 – Treatment of severe and critical SARS-CoV-2-infected patients with

glucocorticoids inhibits ACh release

The production of lipid mediators and the shedding of sCD14 in patients with Covid-19 at the severe and critical stages was not modified by treatment with glucocorticoids (GC). However, a marked reduction was observed in ACh release. Intersection analysis depicted in Venn diagrams revealed the number of patients producing AA, 5-HETE, 11-HETE, ACh, or sCD14, above the control (healthy participants) values, in the absence (A) or presence (B) of GC therapy. The table shows the number (*n*) of plasma or BAL samples from Covid-19 patients at the severe and critical stages of disease, for each mediator. The percentages shown in parentheses represent the frequency of patients producing the respective mediator for the corresponding sample number.

The Venn diagrams show the intersections of AA, 5-HETE, 11-HETE, ACh, and sCD14s in Covid-19 patients at the severe and critical stages of the disease, in both blood and BAL. No significant changes were observed in the quantification of lipid mediators or sCD14, comparing patients treated with or without glucocorticoids (Figure S5A and FigureS5B). Interestingly, critically ill patients treated with glucocorticoids showed a 20% and 65% reduction in the ACh

concentration in both blood and BAL samples, respectively, compared to patients who were not administered drugs (Figure S5B). While a decrease in free-AA and its metabolites (5-HETE and 11-HETE) has not been reported in the literature, some studies have demonstrated the beneficial effects of the use of glucocorticoids in other respiratory syndromes, having been found to reduce the production of AA-derived mediators [72,146]. In agreement with our results, there is no evidence to support corticoid treatment for Covid-19 [147]. Data related to the effect of glucocorticoids on ACh release in viral infections are scarce. However, according to our previous findings on scorpion envenomation[3], glucocorticoid treatment should be initiated early after infection to block the release of lipid mediators, which could lead to the inhibition of premature ACh release. On the contrary, the late administration of GC could place patients at a point of no return, with early ACh release impacting vital organs, damaged by the negative impacts of this neurotransmitter before GC administration. Moreover, it should be considered that, in Covid-19, other unknown mechanisms may control ACh release, in addition to the COX-2 dependent metabolites.

1584   **Figure S6 - Differential expression and profile of genes involved in AA and ACh**

1585   **pathways from SARS-CoV-2 deceased patients**

1586

1587

1588

Abbreviations: CVL, Covid-19 low viral load; CVH, Covid-19 high viral load; NCV,

non-Covid-19 viral load [9,50,110,113].

As shown in (A), DEGs were upregulated in CVL versus CVH patients and CVL

versus NCV patients. The transcript expression of cholinergic receptors (muscarinic and

nicotinic) (B) and eicosanoid receptors (C) was normalised in the NCV, CVH, and CVL

groups. CVL patients displayed increased pulmonary levels of expression of genes

associated with the ACh and AA pathways, encoding for cholinergic receptors, the ACh

release cycle, AA metabolism, and eicosanoid receptors, compared to CVH or NCV

patients. The expression profile of some genes may favour inflammatory events, such as

upregulated cholinergic and eicosanoid receptors (CHRM3, CHRNA3, CHRNA5, and

OXER1) and low levels of the anti-inflammatory cholinergic receptor (CHRNA7)

[9,50,110,113].